User login
Liability of Hospitalist Model of Care
The hospitalist model of care is becoming an increasingly prominent part of the inpatient clinical landscape. The percentage of hospitals in which hospitalists provide care has risen every year since 2003, and this trend is anticipated to continue.[1] In 2010, 59.8% of hospitals reported utilizing hospitalists to provide care, with a prevalence as high as 84.9% in New England.[1] Though the model started within internal medicine,[2] hospitalists can now be found in multiple medical disciplines including pediatrics, neurology, obstetrics‐gynecology, and orthopedics.[3] This model has many strengths, which include an improved provider presence in the hospital for acute issues, as well as a better understanding of hospital operations and knowledge of inpatient care. However, concerns have been raised that the hospitalist model, which does not usually involve longitudinal relationships with patients and introduces discontinuities in care, could carry a higher risk of malpractice claims.[4, 5, 6]
However, little is known about whether the hospitalist model actually leads to greater liability. Theoretical analyses suggest that failure to provide adequate follow up care, especially with regard to tests pending at discharge, may be a source of greater medical liability risk for hospitalists.[7] Coordination of care with consulting specialists and supervision of trainees may also be areas of increased liability risk.[7, 8] Prior research evaluating the difference in malpractice payments between the inpatient and outpatient settings found that the mean payment amounts were significantly higher in the inpatient setting.[9] Another study examined the rates of malpractice claims against physicians and determined that internal medicine physicians were at average risk of claims compared to other specialties.[10] However, none of the available data have provided direct information on liability risks specific to the hospitalist model.
METHODS
Design and Malpractice Claims Data
We conducted a retrospective observational analysis using closed claims data obtained from a liability insurer‐maintained database of over 52,000 coded medical malpractice claims. This database includes claims from 20 different insurance programs providing coverage to over 3000 different organizations, including academic medical centers, community hospitals, and physician groups. Approximately 30% of closed claims in the United States are included in the database. Claims in the database are categorized by allegation type, factors contributing to the error or injury, severity of injury, and claim outcome. Database categorization of claims was performed by trained registered nurses and performed according to prespecified criteria. Data on the number of physician coverage years (PCYs) were available for only one of the medical liability carriers, which covers a number of academic medical centers and community hospitals in New England. Therefore, claims rate analyses are based on information from this one insurer, which included 34,942 PCYs during the study period.
Claims with injury dates from 1997 to 2011 were used for analyses in this study. We chose 1997 as the starting year for the analysis because that was the first year the database formally included hospitalist claims as a separate category. For malpractice claims rates, the period analyzed was for injury dates from 1997 to 2008. We used 2008 as the cutoff for the analysis of claims rates to account for the time lag that can exist between the date of the alleged malpractice and the filing of a malpractice claim. Claims were classified by physician practice specialty, based on the attending physician's specialty at the time of the care that led to the claim. Hospitalists were defined as internal medicine physicians who spend >50% of their time practicing in the inpatient setting. This study was approved by the institutional review board at Brigham and Women's Hospital in Boston, Massachusetts.
Outcome Variables
Our primary outcome was the rate of malpractice claims, expressed as the number of malpractice claims per 100 PCYs. Other outcome variables, including major allegation types, contributing factors, and severity of injury, are reported as number of cases within a given category or subcategory and percentages of cases. The percentages are calculated as the percentage of the total number of claims against hospitalists. Severity of injury is ranked based on the National Association of Insurance Commissioners' Severity of Injury Scale, a standard scale for measuring the severity of injury in tort cases.[11, 12] Payment status refers to whether or not payment was made on a malpractice claim, regardless of whether payment resulted from a court judgment or a settlement. Compensation amounts are adjusted for inflation using the US Bureau of Labor Statistics Consumer Price Index, based on the year of payment and reported in 2011 dollars.[13]
Statistical Analysis
Comparisons between mean and median payment amounts were performed using the Wilcoxon rank sum test, as the distributions of the payment amounts were non‐normal. Comparisons for physician claims rates, severity of injury, and the percentage of cases in which payment was made were performed using Fisher's exact test. Confidence intervals (CIs) for proportions were calculated using the exact (Clopper‐Pearson) method. Tests performed were 2‐sided, with a P value <0.05 considered significant. Statistical analysis was performed using the SAS statistical software package, version 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
We identified 272 medical malpractice claims against hospitalists. The mean age of the claimants was 56 years (standard deviation, 22 years). Claimants were 51.8% female and 44.5% male (gender not available for 3.7%).
The rate of claims against hospitalists (0.52 claims per 100 PCYs; 95% CI: 0.30‐0.85) was significantly lower than the rate of claims against nonhospitalist internal medicine physicians (1.91 claims per 100 PCYs; 95% CI: 1.73‐2.11), as well as the other physician types studied (P<0.001 for all claims rate comparisons) (Table 1). The rate of claims against nonhospitalist internal medicine physicians and emergency medicine physicians were approximately 3.5 times and 7 times, respectively, the rate of claims against hospitalists.
| Hospitalists (Internal Medicine Only) | All Other Internal Medicine Physicians | Emergency Medicine Physicians | General Surgeons | Obstetricians‐Gynecologists | |
|---|---|---|---|---|---|
| |||||
| No. of claims | 16 | 398 | 90 | 191 | 248 |
| Physician coverage years | 3,060 | 20,787 | 2,571 | 4,062 | 4,462 |
| Claims per 100 physician coverage years (95% CI) | 0.52 (0.30‐0.85) | 1.91a (1.73‐2.11) | 3.50a (2.82‐4.29) | 4.70a (4.07‐5.40) | 5.56a (4.90‐6.27) |
The most common types of allegations against hospitalists were for issues related to medical treatment (41.5%; 95% CI: 35.6%‐47.6%) and diagnosis‐related claims (36.0%; 95% CI: 30.3%‐42.0) (Table 2). The most common steps in the diagnostic process implicated in the diagnosis‐related allegations were errors in the ordering of diagnostic or lab tests (16.2%; 95% CI: 12.0%‐21.1%) and the performance of the history and physical (12.1%; 95% CI: 8.5%‐16.6%).
| Category | No. of Cases | % of Cases (95% CI) |
|---|---|---|
| ||
| Medical treatment | 113 | 41.5% (35.6%‐47.6%) |
| Diagnosis relatedb | 98 | 36.0% (30.3%‐42.0%) |
| Patient notes problem and seeks medical care | 2 | 0.7% (0.1%‐2.6%) |
| History/physical and evaluation of symptoms | 33 | 12.1% (8.5%‐16.6%) |
| Ordering of diagnostic/labs tests | 44 | 16.2% (12.0%‐21.1%) |
| Performance of tests | 8 | 2.9% (1.3%‐5.7%) |
| Interpretation of tests | 22 | 8.1% (5.1%‐12.0%) |
| Receipt or transmittal of test results | 8 | 2.9% (1.3%‐5.7%) |
| Physician follow‐up with patient | 6 | 2.2% (0.8%‐4.7%) |
| Referral management or consultation errors | 24 | 8.8% (5.7%‐12.8%) |
| Medication related | 26 | 9.6% (6.3%‐13.7%) |
| Patient monitoring | 12 | 4.4% (2.3%‐7.6%) |
| Surgical treatment | 9 | 3.3% (1.5%‐6.2%) |
The most common categories of contributing factors were errors in clinical judgment (54.4%; 95% CI: 48.3%‐60.4%) and lapses in communication (encompassing communication among clinicians and between the clinician and patient) (36.4%; 95% CI: 30.7%‐42.4%) (Table 3). Issues involving transitions of care were a factor in 37.9% of cases (95% CI: 32.1%‐43.9%). Supervision of housestaff was a factor in 1.5% of cases (95% CI: 0.4%‐3.7%).
| Contributing Factor | No. of Cases | % of Cases (95% CI) | Definition or Example |
|---|---|---|---|
| |||
| Clinical judgment | 148 | 54.4% (48.3%‐60.4%) | Problems with patient assessment or choice of therapy; failure/delay in obtaining consult/referral |
| Failure or delay in ordering a diagnostic test | 36 | 13.2% (9.4%‐17.8%) | |
| Failure or delay in obtaining a consult or referral | 35 | 12.9% (9.1%‐17.4%) | |
| Having too narrow a diagnostic focus | 34 | 12.5% (8.8%‐17.0%) | |
| Communication | 99 | 36.4% (30.7%‐42.4%) | Issues with communication among clinicians or between the clinicians and the patient or family |
| Inadequate communication among providers regarding the patient's condition | 61 | 22.4% (17.6%‐27.9%) | |
| Poor rapport with/lack of sympathy toward and patient and/or family | 15 | 5.5% (3.1%‐8.9%) | |
| Insufficient education of the patient and/or family regarding the risks of medications | 9 | 3.3% (1.5%‐6.2%) | |
| Documentation | 53 | 19.5% (14.9%‐24.7%) | Insufficient or lack of documentation |
| Administrative | 47 | 17.3% (13.0%‐22.3%) | Problems with staffing or hospital policies and protocols |
| Clinical systems | 44 | 16.2% (12.0%‐21.1%) | Failure or delay in scheduling a recommended test or failure to identify the provider coordinating care |
| Behavior related | 28 | 10.3% (7.0%‐14.5%) | Patient not following provider recommendations; seeking other providers due to dissatisfaction with care |
The percentage of claims involving a patient death was significantly higher among hospitalist cases (50.4%; 95% CI: 44.3%‐56.5%) compared to all other inpatient cases (29.1%; 95% CI: 28.4%‐29.8%) or outpatient cases (18.2%; 95% CI: 17.6%‐18.9%) (P<0.001 for both comparisons), but lower than nonhospitalist inpatient internal medicine cases (57.6%; 95% CI: 54.6%‐60.5%) (P=0.035) (Table 4).
| Severitya | Hospitalists Cases, Internal Medicine Only, n=272 | All Other Inpatient Internal Medicine Cases, n=1120 | All Other Inpatient Cases, n=14,386 | Outpatient Cases, n=15,039 | ||||
|---|---|---|---|---|---|---|---|---|
| No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | |
| ||||||||
| Low | 19 | 7.0% (4.3%‐10.7%) | 61 | 5.4% (4.2%‐6.9%) | 1,180 | 8.2% (7.8%‐8.7%) | 2,279 | 15.2%b (14.6%‐15.7%) |
| Medium | 65 | 23.9% (19.0%‐29.4%) | 235 | 21.0% (18.6%‐23.5%) | 6,503 | 45.2%b (44.4%‐46.0%) | 7,803 | 51.9%b (51.1%‐52.7%) |
| High | 188 | 69.1% (63.3%‐74.6%) | 824 | 73.6% (70.9%‐76.1%) | 6,703 | 46.6%b (45.8%‐47.4%) | 4,957 | 33.0%b (32.2%‐33.7%) |
| Death | 137 | 50.4% (44.3%‐56.5%) | 645 | 57.6%c (54.6%‐60.5%) | 4,186 | 29.1%b (28.4%‐29.8%) | 2,744 | 18.2%b (17.6%‐18.9%) |
There were no significant differences in the percentage of hospitalist cases in which payment was made (32.0%; 95% CI: 26.5%‐37.9%) compared to any of the other 3 groups studied (Table 5). The median payment in hospitalist cases, $240,000 (interquartile range [IQR]: $100,000$524,245), was significantly higher than that in all other inpatient cases ($156,714; IQR: $39,188$488,996) (P=0.040) and in outpatient cases ($92,671; IQR: $20,895$325,461) (P<0.001), though not significantly different than the median payment in all other inpatient internal medicine cases ($206,314; IQR: $57,382$488,996).
| Hospitalist Cases, Internal Medicine Only | All Other Inpatient Internal Medicine Cases | All Other Inpatient Cases | Outpatient Cases | |||||
|---|---|---|---|---|---|---|---|---|
| No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | |
| ||||||||
| Payment made | 87 | 32.0% (26.5%‐37.9%) | 330 | 29.5% (26.8%‐32.2%) | 5164 | 35.9% (35.1%‐36.7%) | 4632 | 30.8% (30.1%‐31.5%) |
| No payment made | 185 | 68.0% (62.1%‐73.5%) | 790 | 70.5% (67.8%‐73.2%) | 9222 | 64.1% (63.3%‐64.9%) | 10407 | 69.2% (68.5%‐69.9%) |
| Mean payment (95% CI) | $384,617 ($289,662‐$479,573) | $451,713 ($359,656‐$543,769) | $482,963 ($452,725‐$513,202) | $305,462b ($286,517‐$324,408) | ||||
| Median payment (IQR) | $240,000 ($100,000$524,245) | $206,314 ($57,382$488,996) | $156,714c ($39,188$488,996) | $92,671b ($20,895$325,461) | ||||
| Standard deviation | $445,531 | $850,086 | $1,108,404 | $657,707 | ||||
DISCUSSION
In our analysis of closed medical malpractice claims, we found that hospitalists have a significantly lower rate of claims compared to the other types of physicians studied, including other internal medicine physicians and emergency medicine physicians. Although hospitalists had a relatively low rate of claims, the severity of injury involved in those claims was high.
Prior research has found that the proportion of internal medicine physicians who face a malpractice claim each year is between 7% and 8%.[10] The rate of claims against internal medicine physicians in this prior study was similar to that of emergency medicine physicians, who, like hospitalists, are defined by their site of practice. In addition, both frequently work with acutely ill patients with whom they do not have a longitudinal relationship. However, this prior analysis did not assess for any difference in malpractice risk based on whether internal medicine physicians were practicing primarily as outpatient physicians or as hospitalists, and so the liability risk of hospitalists (as opposed to internal medicine physicians generally) remains undefined. Our analysis sought to determine whether there is a difference in claims rates when adopting a hospitalist model.
Notably, two factors have been raised as potentially increasing the risk that hospitalists will be subject to malpractice claims. The first is that hospitalists have only a brief relationship with their patients, thus limiting their ability to form the strong physician‐patient relationships that decrease the likelihood of a malpractice claim.[14, 15, 16, 17] Second, hospitalists face the challenge of transitions of care as patients move from the outpatient to the inpatient setting, and vice versa.[4, 7, 18, 19] Despite these theoretical concerns, we found that hospitalists face a relatively low rate of claims compared to other physicians. The reasons for this low liability risk remain uncertain.
One possible explanation for this relatively low rate of claims against hospitalists is that hospitalists are actually at lower risk of missing a diagnosis, the most common reason for a malpractice claim in the ambulatory setting.[20, 21, 22] In contrast to how patients may present in the clinic or the emergency department, when patients are admitted to the hospital, it is likely that they present to the hospitalist with a known problem, rather than a clinical symptom without an etiology. For example, when a patient is admitted to the hospital for chest pain, other physicians may have already been concerned enough to raise clinical suspicion of a myocardial infarction and order basic testing, making the diagnosis less likely to be missed when the hospitalist assumes care of that patient. Indeed, we found that, among the claims made against hospitalists, the leading type of allegation was an error in treatment rather than an error in diagnosis.
It is also possible that the lower rate of claims against hospitalists reflects the high quality of care provided by hospitalists, resulting from their clinical expertise and knowledge of hospital systems. High clinical volume is associated with better outcomes for multiple surgical procedures,[23] and, to a lesser degree, for certain medical conditions.[24] Because hospitalists are likely to see a high volume of those medical conditions that regularly require admission to an inpatient medical service, this high volume could translate into higher quality of care, both because of medical expertise in managing these conditions and because of proficiency in dealing with hospital systems. However, this theory must be tempered by the conclusion from earlier work that did not show a large difference in outcomes among patients cared for by hospitalists.[25]
Another reason for the lower claims rate could be a direct result of how hospitalist jobs are structured. In prior research, an inadequate physician‐patient relationship has been found to be a factor in patients deciding to file a malpractice claim.[14, 15, 16, 17] Although hospitalists usually only care for their patients during the few days of the hospital admission, hospitalists are on site all day and thus are able to frequently communicate with patients and families face to face. This level of interaction may allow for a sufficiently healthy, even if time‐limited, physician‐patient relationship that meets patients' expectations.
For the claims that occur, deficiencies in communication and transitions of care, both of which have been cited as a special concern for hospitalists, were in fact present in 37.9% of the hospitalist cases we evaluated.[7] This proportion appears to be higher than previous work in the ambulatory setting that showed communication generally to be a factor in 30% of cases, and problems related to handoffs specifically to be a factor in 20% of cases.[20] These findings highlight the risks associated with the discontinuities inherent in the hospitalist model, which can occur on admission, during the hospitalization (where a number of hospitalists may care for one patient), and on discharge. These findings also point to the need for ongoing efforts to address these concerns.
More than half of the claims against hospitalists (50.4%; 95% CI: 44.3%‐56.5%) involved the death of the patient. However, this high rate of claims involving the death of the patient did not appear to be specific to hospitalists. Rather, this appeared to be true for inpatient internal medicine cases generally, because the rate of claims in which the severity of injury was death was significantly higher among nonhospitalist inpatient internal medicine cases (57.6%; 95% CI: 54.6%‐60.5%).
Our study has several limitations. Though the database that we used includes hospitals and physician groups from 20 different liability carriers covering multiple regions across the country, it nonetheless may not be entirely representative, especially given the variation in the hospitalist models used at different institutions (for example, coverage of intensive care unit patients) and because of geographic variability. However, the sample did contain a large proportion (approximately 30%) of closed claims nationally. Claims rates are based on data from a single insurance carrier, albeit one with 23,847 PCYs among internal medicine physicians during the study period. Second, we defined hospitalist cases as those cases in which the hospitalist was the attending of record at the time of the clinical event that gave rise to the malpractice claim. It is possible that this definition captured claims in which the hospitalist, although the attending of record, may not have been directly involved in the care leading to the claim (for example, a problem with a surgery gave rise to the claim). Third, we assessed liability risk by years covered, which does not account for risk that may vary based on clinical volume.
Overall, our results suggest that liability fears should not impede the adoption of the hospitalist model in internal medicine. Not only do hospitalists have a lower rate of claims, but there is also no difference in the rate at which claims are paid or mean indemnity amounts for the claims that are paid for hospitalists. Previous analyses of the costs associated with care by hospitalists, compared to care by other types of physicians, have not taken into account the decreased liability costs that are likely associated with care provided by hospitalists.[25, 26]
In conclusion, contrary to concerns that have been raised, we found that hospitalists face a lower rate of malpractice claims when compared to other internal medicine physicians and specialties. However, we did find that care discontinuities may be resulting in liability risk due to communication and handoff‐related errors. Improvements in the hospitalist model of care targeted at improving communication and clinical judgment may not only further reduce claims against hospitalists, but also improve the safety of care associated with this model.
Disclosures
Dr. Kachalia has received honoraria from Quantia MD for presentations on patient safety. Dr. Schaffer, Ms. Raman, and Ms. Puopolo have no disclosures. The authors report no conflicts of interest.
- American Hospital Association. AHA Hospital Statistics. 2012 ed. Chicago, IL: Health Forum; 2012.
- , . The emerging role of "hospitalists" in the American health care system. N Engl J Med. 1996;335(7):514–517.
- , , . Specialty hospitalists: analyzing an emerging phenomenon. JAMA. 2012;307(16):1699–1700.
- , , , . Primary care physician attitudes regarding communication with hospitalists. Am J Med. 2001;111(9B):15S–20S.
- . Hospitalists and the doctor‐patient relationship. J Legal Stud. 2001;30(2):589–606.
- . Rapport and the hospitalist. Am J Med. 2001;111(9B):31S–35S.
- . Key legal principles for hospitalists. Am J Med. 2001;111(9B):5S–9S.
- , . Medical malpractice. In: McKean S, Ross J, Dressler D, Brotman D, Ginsberg J, eds. Principles and Practice of Hospital Medicine. New York, NY: McGraw Hill; 2012.
- , , . Paid malpractice claims for adverse events in inpatient and outpatient settings. JAMA. 2011;305(23):2427–2431.
- , , , . Malpractice risk according to physician specialty. N Engl J Med. 2011;365(7):629–636.
- Sowka MP, ed. NAIC Malpractice Claims, Final Compilation. Brookfield, WI: National Association of Insurance Commissioners; 1980.
- , . Medical Malpractice Insurance Claims in Seven States, 2000–2004. U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics Special Report; March 2007.
- Bureau of Labor Statistics. Available at: http://data.bls.gov/pdq/querytool.jsp?survey=cu. Accessed December 3, 2012.
- , , , . The doctor‐patient relationship and malpractice. Lessons from plaintiff depositions. Arch Intern Med. 1994;154(12):1365–1370.
- , , , . Factors that prompted families to file medical malpractice claims following perinatal injuries. JAMA. 1992;267(10):1359–1363.
- , , . Why do people sue doctors? A study of patients and relatives taking legal action. Lancet. 1994;343(8913):1609–1613.
- , , , , . Physician‐patient communication. The relationship with malpractice claims among primary care physicians and surgeons. JAMA. 1997;277(7):553–559.
- , , , . Medical errors related to discontinuity of care from an inpatient to an outpatient setting. J Gen Intern Med. 2003;18(8):646–651.
- , . The ethics of the hospitalist model. J Hosp Med. 2010;5(3):183–188.
- , , , et al. Missed and delayed diagnoses in the ambulatory setting: a study of closed malpractice claims. Ann Intern Med. 2006;145(7):488–496.
- , , , , , . Learning from malpractice claims about negligent, adverse events in primary care in the United States. Qual Saf Health Care. 2004;13(2):121–126.
- , , , et al. Primary care closed claims experience of Massachusetts malpractice insurers. JAMA Intern Med. 2013;173(22):2063–2068.
- , , , et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–1137.
- , , , et al. Hospital volume and 30‐day mortality for three common medical conditions. N Engl J Med. 2010;362(12):1110–1118.
- , , , , , . Outcomes of care by hospitalists, general internists, and family physicians. N Engl J Med. 2007;357(25):2589–2600.
- , , , et al. Quality of care for decompensated heart failure: comparable performance between academic hospitalists and non‐hospitalists. J Gen Intern Med. 2008;23(9):1399–1406.
The hospitalist model of care is becoming an increasingly prominent part of the inpatient clinical landscape. The percentage of hospitals in which hospitalists provide care has risen every year since 2003, and this trend is anticipated to continue.[1] In 2010, 59.8% of hospitals reported utilizing hospitalists to provide care, with a prevalence as high as 84.9% in New England.[1] Though the model started within internal medicine,[2] hospitalists can now be found in multiple medical disciplines including pediatrics, neurology, obstetrics‐gynecology, and orthopedics.[3] This model has many strengths, which include an improved provider presence in the hospital for acute issues, as well as a better understanding of hospital operations and knowledge of inpatient care. However, concerns have been raised that the hospitalist model, which does not usually involve longitudinal relationships with patients and introduces discontinuities in care, could carry a higher risk of malpractice claims.[4, 5, 6]
However, little is known about whether the hospitalist model actually leads to greater liability. Theoretical analyses suggest that failure to provide adequate follow up care, especially with regard to tests pending at discharge, may be a source of greater medical liability risk for hospitalists.[7] Coordination of care with consulting specialists and supervision of trainees may also be areas of increased liability risk.[7, 8] Prior research evaluating the difference in malpractice payments between the inpatient and outpatient settings found that the mean payment amounts were significantly higher in the inpatient setting.[9] Another study examined the rates of malpractice claims against physicians and determined that internal medicine physicians were at average risk of claims compared to other specialties.[10] However, none of the available data have provided direct information on liability risks specific to the hospitalist model.
METHODS
Design and Malpractice Claims Data
We conducted a retrospective observational analysis using closed claims data obtained from a liability insurer‐maintained database of over 52,000 coded medical malpractice claims. This database includes claims from 20 different insurance programs providing coverage to over 3000 different organizations, including academic medical centers, community hospitals, and physician groups. Approximately 30% of closed claims in the United States are included in the database. Claims in the database are categorized by allegation type, factors contributing to the error or injury, severity of injury, and claim outcome. Database categorization of claims was performed by trained registered nurses and performed according to prespecified criteria. Data on the number of physician coverage years (PCYs) were available for only one of the medical liability carriers, which covers a number of academic medical centers and community hospitals in New England. Therefore, claims rate analyses are based on information from this one insurer, which included 34,942 PCYs during the study period.
Claims with injury dates from 1997 to 2011 were used for analyses in this study. We chose 1997 as the starting year for the analysis because that was the first year the database formally included hospitalist claims as a separate category. For malpractice claims rates, the period analyzed was for injury dates from 1997 to 2008. We used 2008 as the cutoff for the analysis of claims rates to account for the time lag that can exist between the date of the alleged malpractice and the filing of a malpractice claim. Claims were classified by physician practice specialty, based on the attending physician's specialty at the time of the care that led to the claim. Hospitalists were defined as internal medicine physicians who spend >50% of their time practicing in the inpatient setting. This study was approved by the institutional review board at Brigham and Women's Hospital in Boston, Massachusetts.
Outcome Variables
Our primary outcome was the rate of malpractice claims, expressed as the number of malpractice claims per 100 PCYs. Other outcome variables, including major allegation types, contributing factors, and severity of injury, are reported as number of cases within a given category or subcategory and percentages of cases. The percentages are calculated as the percentage of the total number of claims against hospitalists. Severity of injury is ranked based on the National Association of Insurance Commissioners' Severity of Injury Scale, a standard scale for measuring the severity of injury in tort cases.[11, 12] Payment status refers to whether or not payment was made on a malpractice claim, regardless of whether payment resulted from a court judgment or a settlement. Compensation amounts are adjusted for inflation using the US Bureau of Labor Statistics Consumer Price Index, based on the year of payment and reported in 2011 dollars.[13]
Statistical Analysis
Comparisons between mean and median payment amounts were performed using the Wilcoxon rank sum test, as the distributions of the payment amounts were non‐normal. Comparisons for physician claims rates, severity of injury, and the percentage of cases in which payment was made were performed using Fisher's exact test. Confidence intervals (CIs) for proportions were calculated using the exact (Clopper‐Pearson) method. Tests performed were 2‐sided, with a P value <0.05 considered significant. Statistical analysis was performed using the SAS statistical software package, version 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
We identified 272 medical malpractice claims against hospitalists. The mean age of the claimants was 56 years (standard deviation, 22 years). Claimants were 51.8% female and 44.5% male (gender not available for 3.7%).
The rate of claims against hospitalists (0.52 claims per 100 PCYs; 95% CI: 0.30‐0.85) was significantly lower than the rate of claims against nonhospitalist internal medicine physicians (1.91 claims per 100 PCYs; 95% CI: 1.73‐2.11), as well as the other physician types studied (P<0.001 for all claims rate comparisons) (Table 1). The rate of claims against nonhospitalist internal medicine physicians and emergency medicine physicians were approximately 3.5 times and 7 times, respectively, the rate of claims against hospitalists.
| Hospitalists (Internal Medicine Only) | All Other Internal Medicine Physicians | Emergency Medicine Physicians | General Surgeons | Obstetricians‐Gynecologists | |
|---|---|---|---|---|---|
| |||||
| No. of claims | 16 | 398 | 90 | 191 | 248 |
| Physician coverage years | 3,060 | 20,787 | 2,571 | 4,062 | 4,462 |
| Claims per 100 physician coverage years (95% CI) | 0.52 (0.30‐0.85) | 1.91a (1.73‐2.11) | 3.50a (2.82‐4.29) | 4.70a (4.07‐5.40) | 5.56a (4.90‐6.27) |
The most common types of allegations against hospitalists were for issues related to medical treatment (41.5%; 95% CI: 35.6%‐47.6%) and diagnosis‐related claims (36.0%; 95% CI: 30.3%‐42.0) (Table 2). The most common steps in the diagnostic process implicated in the diagnosis‐related allegations were errors in the ordering of diagnostic or lab tests (16.2%; 95% CI: 12.0%‐21.1%) and the performance of the history and physical (12.1%; 95% CI: 8.5%‐16.6%).
| Category | No. of Cases | % of Cases (95% CI) |
|---|---|---|
| ||
| Medical treatment | 113 | 41.5% (35.6%‐47.6%) |
| Diagnosis relatedb | 98 | 36.0% (30.3%‐42.0%) |
| Patient notes problem and seeks medical care | 2 | 0.7% (0.1%‐2.6%) |
| History/physical and evaluation of symptoms | 33 | 12.1% (8.5%‐16.6%) |
| Ordering of diagnostic/labs tests | 44 | 16.2% (12.0%‐21.1%) |
| Performance of tests | 8 | 2.9% (1.3%‐5.7%) |
| Interpretation of tests | 22 | 8.1% (5.1%‐12.0%) |
| Receipt or transmittal of test results | 8 | 2.9% (1.3%‐5.7%) |
| Physician follow‐up with patient | 6 | 2.2% (0.8%‐4.7%) |
| Referral management or consultation errors | 24 | 8.8% (5.7%‐12.8%) |
| Medication related | 26 | 9.6% (6.3%‐13.7%) |
| Patient monitoring | 12 | 4.4% (2.3%‐7.6%) |
| Surgical treatment | 9 | 3.3% (1.5%‐6.2%) |
The most common categories of contributing factors were errors in clinical judgment (54.4%; 95% CI: 48.3%‐60.4%) and lapses in communication (encompassing communication among clinicians and between the clinician and patient) (36.4%; 95% CI: 30.7%‐42.4%) (Table 3). Issues involving transitions of care were a factor in 37.9% of cases (95% CI: 32.1%‐43.9%). Supervision of housestaff was a factor in 1.5% of cases (95% CI: 0.4%‐3.7%).
| Contributing Factor | No. of Cases | % of Cases (95% CI) | Definition or Example |
|---|---|---|---|
| |||
| Clinical judgment | 148 | 54.4% (48.3%‐60.4%) | Problems with patient assessment or choice of therapy; failure/delay in obtaining consult/referral |
| Failure or delay in ordering a diagnostic test | 36 | 13.2% (9.4%‐17.8%) | |
| Failure or delay in obtaining a consult or referral | 35 | 12.9% (9.1%‐17.4%) | |
| Having too narrow a diagnostic focus | 34 | 12.5% (8.8%‐17.0%) | |
| Communication | 99 | 36.4% (30.7%‐42.4%) | Issues with communication among clinicians or between the clinicians and the patient or family |
| Inadequate communication among providers regarding the patient's condition | 61 | 22.4% (17.6%‐27.9%) | |
| Poor rapport with/lack of sympathy toward and patient and/or family | 15 | 5.5% (3.1%‐8.9%) | |
| Insufficient education of the patient and/or family regarding the risks of medications | 9 | 3.3% (1.5%‐6.2%) | |
| Documentation | 53 | 19.5% (14.9%‐24.7%) | Insufficient or lack of documentation |
| Administrative | 47 | 17.3% (13.0%‐22.3%) | Problems with staffing or hospital policies and protocols |
| Clinical systems | 44 | 16.2% (12.0%‐21.1%) | Failure or delay in scheduling a recommended test or failure to identify the provider coordinating care |
| Behavior related | 28 | 10.3% (7.0%‐14.5%) | Patient not following provider recommendations; seeking other providers due to dissatisfaction with care |
The percentage of claims involving a patient death was significantly higher among hospitalist cases (50.4%; 95% CI: 44.3%‐56.5%) compared to all other inpatient cases (29.1%; 95% CI: 28.4%‐29.8%) or outpatient cases (18.2%; 95% CI: 17.6%‐18.9%) (P<0.001 for both comparisons), but lower than nonhospitalist inpatient internal medicine cases (57.6%; 95% CI: 54.6%‐60.5%) (P=0.035) (Table 4).
| Severitya | Hospitalists Cases, Internal Medicine Only, n=272 | All Other Inpatient Internal Medicine Cases, n=1120 | All Other Inpatient Cases, n=14,386 | Outpatient Cases, n=15,039 | ||||
|---|---|---|---|---|---|---|---|---|
| No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | |
| ||||||||
| Low | 19 | 7.0% (4.3%‐10.7%) | 61 | 5.4% (4.2%‐6.9%) | 1,180 | 8.2% (7.8%‐8.7%) | 2,279 | 15.2%b (14.6%‐15.7%) |
| Medium | 65 | 23.9% (19.0%‐29.4%) | 235 | 21.0% (18.6%‐23.5%) | 6,503 | 45.2%b (44.4%‐46.0%) | 7,803 | 51.9%b (51.1%‐52.7%) |
| High | 188 | 69.1% (63.3%‐74.6%) | 824 | 73.6% (70.9%‐76.1%) | 6,703 | 46.6%b (45.8%‐47.4%) | 4,957 | 33.0%b (32.2%‐33.7%) |
| Death | 137 | 50.4% (44.3%‐56.5%) | 645 | 57.6%c (54.6%‐60.5%) | 4,186 | 29.1%b (28.4%‐29.8%) | 2,744 | 18.2%b (17.6%‐18.9%) |
There were no significant differences in the percentage of hospitalist cases in which payment was made (32.0%; 95% CI: 26.5%‐37.9%) compared to any of the other 3 groups studied (Table 5). The median payment in hospitalist cases, $240,000 (interquartile range [IQR]: $100,000$524,245), was significantly higher than that in all other inpatient cases ($156,714; IQR: $39,188$488,996) (P=0.040) and in outpatient cases ($92,671; IQR: $20,895$325,461) (P<0.001), though not significantly different than the median payment in all other inpatient internal medicine cases ($206,314; IQR: $57,382$488,996).
| Hospitalist Cases, Internal Medicine Only | All Other Inpatient Internal Medicine Cases | All Other Inpatient Cases | Outpatient Cases | |||||
|---|---|---|---|---|---|---|---|---|
| No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | |
| ||||||||
| Payment made | 87 | 32.0% (26.5%‐37.9%) | 330 | 29.5% (26.8%‐32.2%) | 5164 | 35.9% (35.1%‐36.7%) | 4632 | 30.8% (30.1%‐31.5%) |
| No payment made | 185 | 68.0% (62.1%‐73.5%) | 790 | 70.5% (67.8%‐73.2%) | 9222 | 64.1% (63.3%‐64.9%) | 10407 | 69.2% (68.5%‐69.9%) |
| Mean payment (95% CI) | $384,617 ($289,662‐$479,573) | $451,713 ($359,656‐$543,769) | $482,963 ($452,725‐$513,202) | $305,462b ($286,517‐$324,408) | ||||
| Median payment (IQR) | $240,000 ($100,000$524,245) | $206,314 ($57,382$488,996) | $156,714c ($39,188$488,996) | $92,671b ($20,895$325,461) | ||||
| Standard deviation | $445,531 | $850,086 | $1,108,404 | $657,707 | ||||
DISCUSSION
In our analysis of closed medical malpractice claims, we found that hospitalists have a significantly lower rate of claims compared to the other types of physicians studied, including other internal medicine physicians and emergency medicine physicians. Although hospitalists had a relatively low rate of claims, the severity of injury involved in those claims was high.
Prior research has found that the proportion of internal medicine physicians who face a malpractice claim each year is between 7% and 8%.[10] The rate of claims against internal medicine physicians in this prior study was similar to that of emergency medicine physicians, who, like hospitalists, are defined by their site of practice. In addition, both frequently work with acutely ill patients with whom they do not have a longitudinal relationship. However, this prior analysis did not assess for any difference in malpractice risk based on whether internal medicine physicians were practicing primarily as outpatient physicians or as hospitalists, and so the liability risk of hospitalists (as opposed to internal medicine physicians generally) remains undefined. Our analysis sought to determine whether there is a difference in claims rates when adopting a hospitalist model.
Notably, two factors have been raised as potentially increasing the risk that hospitalists will be subject to malpractice claims. The first is that hospitalists have only a brief relationship with their patients, thus limiting their ability to form the strong physician‐patient relationships that decrease the likelihood of a malpractice claim.[14, 15, 16, 17] Second, hospitalists face the challenge of transitions of care as patients move from the outpatient to the inpatient setting, and vice versa.[4, 7, 18, 19] Despite these theoretical concerns, we found that hospitalists face a relatively low rate of claims compared to other physicians. The reasons for this low liability risk remain uncertain.
One possible explanation for this relatively low rate of claims against hospitalists is that hospitalists are actually at lower risk of missing a diagnosis, the most common reason for a malpractice claim in the ambulatory setting.[20, 21, 22] In contrast to how patients may present in the clinic or the emergency department, when patients are admitted to the hospital, it is likely that they present to the hospitalist with a known problem, rather than a clinical symptom without an etiology. For example, when a patient is admitted to the hospital for chest pain, other physicians may have already been concerned enough to raise clinical suspicion of a myocardial infarction and order basic testing, making the diagnosis less likely to be missed when the hospitalist assumes care of that patient. Indeed, we found that, among the claims made against hospitalists, the leading type of allegation was an error in treatment rather than an error in diagnosis.
It is also possible that the lower rate of claims against hospitalists reflects the high quality of care provided by hospitalists, resulting from their clinical expertise and knowledge of hospital systems. High clinical volume is associated with better outcomes for multiple surgical procedures,[23] and, to a lesser degree, for certain medical conditions.[24] Because hospitalists are likely to see a high volume of those medical conditions that regularly require admission to an inpatient medical service, this high volume could translate into higher quality of care, both because of medical expertise in managing these conditions and because of proficiency in dealing with hospital systems. However, this theory must be tempered by the conclusion from earlier work that did not show a large difference in outcomes among patients cared for by hospitalists.[25]
Another reason for the lower claims rate could be a direct result of how hospitalist jobs are structured. In prior research, an inadequate physician‐patient relationship has been found to be a factor in patients deciding to file a malpractice claim.[14, 15, 16, 17] Although hospitalists usually only care for their patients during the few days of the hospital admission, hospitalists are on site all day and thus are able to frequently communicate with patients and families face to face. This level of interaction may allow for a sufficiently healthy, even if time‐limited, physician‐patient relationship that meets patients' expectations.
For the claims that occur, deficiencies in communication and transitions of care, both of which have been cited as a special concern for hospitalists, were in fact present in 37.9% of the hospitalist cases we evaluated.[7] This proportion appears to be higher than previous work in the ambulatory setting that showed communication generally to be a factor in 30% of cases, and problems related to handoffs specifically to be a factor in 20% of cases.[20] These findings highlight the risks associated with the discontinuities inherent in the hospitalist model, which can occur on admission, during the hospitalization (where a number of hospitalists may care for one patient), and on discharge. These findings also point to the need for ongoing efforts to address these concerns.
More than half of the claims against hospitalists (50.4%; 95% CI: 44.3%‐56.5%) involved the death of the patient. However, this high rate of claims involving the death of the patient did not appear to be specific to hospitalists. Rather, this appeared to be true for inpatient internal medicine cases generally, because the rate of claims in which the severity of injury was death was significantly higher among nonhospitalist inpatient internal medicine cases (57.6%; 95% CI: 54.6%‐60.5%).
Our study has several limitations. Though the database that we used includes hospitals and physician groups from 20 different liability carriers covering multiple regions across the country, it nonetheless may not be entirely representative, especially given the variation in the hospitalist models used at different institutions (for example, coverage of intensive care unit patients) and because of geographic variability. However, the sample did contain a large proportion (approximately 30%) of closed claims nationally. Claims rates are based on data from a single insurance carrier, albeit one with 23,847 PCYs among internal medicine physicians during the study period. Second, we defined hospitalist cases as those cases in which the hospitalist was the attending of record at the time of the clinical event that gave rise to the malpractice claim. It is possible that this definition captured claims in which the hospitalist, although the attending of record, may not have been directly involved in the care leading to the claim (for example, a problem with a surgery gave rise to the claim). Third, we assessed liability risk by years covered, which does not account for risk that may vary based on clinical volume.
Overall, our results suggest that liability fears should not impede the adoption of the hospitalist model in internal medicine. Not only do hospitalists have a lower rate of claims, but there is also no difference in the rate at which claims are paid or mean indemnity amounts for the claims that are paid for hospitalists. Previous analyses of the costs associated with care by hospitalists, compared to care by other types of physicians, have not taken into account the decreased liability costs that are likely associated with care provided by hospitalists.[25, 26]
In conclusion, contrary to concerns that have been raised, we found that hospitalists face a lower rate of malpractice claims when compared to other internal medicine physicians and specialties. However, we did find that care discontinuities may be resulting in liability risk due to communication and handoff‐related errors. Improvements in the hospitalist model of care targeted at improving communication and clinical judgment may not only further reduce claims against hospitalists, but also improve the safety of care associated with this model.
Disclosures
Dr. Kachalia has received honoraria from Quantia MD for presentations on patient safety. Dr. Schaffer, Ms. Raman, and Ms. Puopolo have no disclosures. The authors report no conflicts of interest.
The hospitalist model of care is becoming an increasingly prominent part of the inpatient clinical landscape. The percentage of hospitals in which hospitalists provide care has risen every year since 2003, and this trend is anticipated to continue.[1] In 2010, 59.8% of hospitals reported utilizing hospitalists to provide care, with a prevalence as high as 84.9% in New England.[1] Though the model started within internal medicine,[2] hospitalists can now be found in multiple medical disciplines including pediatrics, neurology, obstetrics‐gynecology, and orthopedics.[3] This model has many strengths, which include an improved provider presence in the hospital for acute issues, as well as a better understanding of hospital operations and knowledge of inpatient care. However, concerns have been raised that the hospitalist model, which does not usually involve longitudinal relationships with patients and introduces discontinuities in care, could carry a higher risk of malpractice claims.[4, 5, 6]
However, little is known about whether the hospitalist model actually leads to greater liability. Theoretical analyses suggest that failure to provide adequate follow up care, especially with regard to tests pending at discharge, may be a source of greater medical liability risk for hospitalists.[7] Coordination of care with consulting specialists and supervision of trainees may also be areas of increased liability risk.[7, 8] Prior research evaluating the difference in malpractice payments between the inpatient and outpatient settings found that the mean payment amounts were significantly higher in the inpatient setting.[9] Another study examined the rates of malpractice claims against physicians and determined that internal medicine physicians were at average risk of claims compared to other specialties.[10] However, none of the available data have provided direct information on liability risks specific to the hospitalist model.
METHODS
Design and Malpractice Claims Data
We conducted a retrospective observational analysis using closed claims data obtained from a liability insurer‐maintained database of over 52,000 coded medical malpractice claims. This database includes claims from 20 different insurance programs providing coverage to over 3000 different organizations, including academic medical centers, community hospitals, and physician groups. Approximately 30% of closed claims in the United States are included in the database. Claims in the database are categorized by allegation type, factors contributing to the error or injury, severity of injury, and claim outcome. Database categorization of claims was performed by trained registered nurses and performed according to prespecified criteria. Data on the number of physician coverage years (PCYs) were available for only one of the medical liability carriers, which covers a number of academic medical centers and community hospitals in New England. Therefore, claims rate analyses are based on information from this one insurer, which included 34,942 PCYs during the study period.
Claims with injury dates from 1997 to 2011 were used for analyses in this study. We chose 1997 as the starting year for the analysis because that was the first year the database formally included hospitalist claims as a separate category. For malpractice claims rates, the period analyzed was for injury dates from 1997 to 2008. We used 2008 as the cutoff for the analysis of claims rates to account for the time lag that can exist between the date of the alleged malpractice and the filing of a malpractice claim. Claims were classified by physician practice specialty, based on the attending physician's specialty at the time of the care that led to the claim. Hospitalists were defined as internal medicine physicians who spend >50% of their time practicing in the inpatient setting. This study was approved by the institutional review board at Brigham and Women's Hospital in Boston, Massachusetts.
Outcome Variables
Our primary outcome was the rate of malpractice claims, expressed as the number of malpractice claims per 100 PCYs. Other outcome variables, including major allegation types, contributing factors, and severity of injury, are reported as number of cases within a given category or subcategory and percentages of cases. The percentages are calculated as the percentage of the total number of claims against hospitalists. Severity of injury is ranked based on the National Association of Insurance Commissioners' Severity of Injury Scale, a standard scale for measuring the severity of injury in tort cases.[11, 12] Payment status refers to whether or not payment was made on a malpractice claim, regardless of whether payment resulted from a court judgment or a settlement. Compensation amounts are adjusted for inflation using the US Bureau of Labor Statistics Consumer Price Index, based on the year of payment and reported in 2011 dollars.[13]
Statistical Analysis
Comparisons between mean and median payment amounts were performed using the Wilcoxon rank sum test, as the distributions of the payment amounts were non‐normal. Comparisons for physician claims rates, severity of injury, and the percentage of cases in which payment was made were performed using Fisher's exact test. Confidence intervals (CIs) for proportions were calculated using the exact (Clopper‐Pearson) method. Tests performed were 2‐sided, with a P value <0.05 considered significant. Statistical analysis was performed using the SAS statistical software package, version 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
We identified 272 medical malpractice claims against hospitalists. The mean age of the claimants was 56 years (standard deviation, 22 years). Claimants were 51.8% female and 44.5% male (gender not available for 3.7%).
The rate of claims against hospitalists (0.52 claims per 100 PCYs; 95% CI: 0.30‐0.85) was significantly lower than the rate of claims against nonhospitalist internal medicine physicians (1.91 claims per 100 PCYs; 95% CI: 1.73‐2.11), as well as the other physician types studied (P<0.001 for all claims rate comparisons) (Table 1). The rate of claims against nonhospitalist internal medicine physicians and emergency medicine physicians were approximately 3.5 times and 7 times, respectively, the rate of claims against hospitalists.
| Hospitalists (Internal Medicine Only) | All Other Internal Medicine Physicians | Emergency Medicine Physicians | General Surgeons | Obstetricians‐Gynecologists | |
|---|---|---|---|---|---|
| |||||
| No. of claims | 16 | 398 | 90 | 191 | 248 |
| Physician coverage years | 3,060 | 20,787 | 2,571 | 4,062 | 4,462 |
| Claims per 100 physician coverage years (95% CI) | 0.52 (0.30‐0.85) | 1.91a (1.73‐2.11) | 3.50a (2.82‐4.29) | 4.70a (4.07‐5.40) | 5.56a (4.90‐6.27) |
The most common types of allegations against hospitalists were for issues related to medical treatment (41.5%; 95% CI: 35.6%‐47.6%) and diagnosis‐related claims (36.0%; 95% CI: 30.3%‐42.0) (Table 2). The most common steps in the diagnostic process implicated in the diagnosis‐related allegations were errors in the ordering of diagnostic or lab tests (16.2%; 95% CI: 12.0%‐21.1%) and the performance of the history and physical (12.1%; 95% CI: 8.5%‐16.6%).
| Category | No. of Cases | % of Cases (95% CI) |
|---|---|---|
| ||
| Medical treatment | 113 | 41.5% (35.6%‐47.6%) |
| Diagnosis relatedb | 98 | 36.0% (30.3%‐42.0%) |
| Patient notes problem and seeks medical care | 2 | 0.7% (0.1%‐2.6%) |
| History/physical and evaluation of symptoms | 33 | 12.1% (8.5%‐16.6%) |
| Ordering of diagnostic/labs tests | 44 | 16.2% (12.0%‐21.1%) |
| Performance of tests | 8 | 2.9% (1.3%‐5.7%) |
| Interpretation of tests | 22 | 8.1% (5.1%‐12.0%) |
| Receipt or transmittal of test results | 8 | 2.9% (1.3%‐5.7%) |
| Physician follow‐up with patient | 6 | 2.2% (0.8%‐4.7%) |
| Referral management or consultation errors | 24 | 8.8% (5.7%‐12.8%) |
| Medication related | 26 | 9.6% (6.3%‐13.7%) |
| Patient monitoring | 12 | 4.4% (2.3%‐7.6%) |
| Surgical treatment | 9 | 3.3% (1.5%‐6.2%) |
The most common categories of contributing factors were errors in clinical judgment (54.4%; 95% CI: 48.3%‐60.4%) and lapses in communication (encompassing communication among clinicians and between the clinician and patient) (36.4%; 95% CI: 30.7%‐42.4%) (Table 3). Issues involving transitions of care were a factor in 37.9% of cases (95% CI: 32.1%‐43.9%). Supervision of housestaff was a factor in 1.5% of cases (95% CI: 0.4%‐3.7%).
| Contributing Factor | No. of Cases | % of Cases (95% CI) | Definition or Example |
|---|---|---|---|
| |||
| Clinical judgment | 148 | 54.4% (48.3%‐60.4%) | Problems with patient assessment or choice of therapy; failure/delay in obtaining consult/referral |
| Failure or delay in ordering a diagnostic test | 36 | 13.2% (9.4%‐17.8%) | |
| Failure or delay in obtaining a consult or referral | 35 | 12.9% (9.1%‐17.4%) | |
| Having too narrow a diagnostic focus | 34 | 12.5% (8.8%‐17.0%) | |
| Communication | 99 | 36.4% (30.7%‐42.4%) | Issues with communication among clinicians or between the clinicians and the patient or family |
| Inadequate communication among providers regarding the patient's condition | 61 | 22.4% (17.6%‐27.9%) | |
| Poor rapport with/lack of sympathy toward and patient and/or family | 15 | 5.5% (3.1%‐8.9%) | |
| Insufficient education of the patient and/or family regarding the risks of medications | 9 | 3.3% (1.5%‐6.2%) | |
| Documentation | 53 | 19.5% (14.9%‐24.7%) | Insufficient or lack of documentation |
| Administrative | 47 | 17.3% (13.0%‐22.3%) | Problems with staffing or hospital policies and protocols |
| Clinical systems | 44 | 16.2% (12.0%‐21.1%) | Failure or delay in scheduling a recommended test or failure to identify the provider coordinating care |
| Behavior related | 28 | 10.3% (7.0%‐14.5%) | Patient not following provider recommendations; seeking other providers due to dissatisfaction with care |
The percentage of claims involving a patient death was significantly higher among hospitalist cases (50.4%; 95% CI: 44.3%‐56.5%) compared to all other inpatient cases (29.1%; 95% CI: 28.4%‐29.8%) or outpatient cases (18.2%; 95% CI: 17.6%‐18.9%) (P<0.001 for both comparisons), but lower than nonhospitalist inpatient internal medicine cases (57.6%; 95% CI: 54.6%‐60.5%) (P=0.035) (Table 4).
| Severitya | Hospitalists Cases, Internal Medicine Only, n=272 | All Other Inpatient Internal Medicine Cases, n=1120 | All Other Inpatient Cases, n=14,386 | Outpatient Cases, n=15,039 | ||||
|---|---|---|---|---|---|---|---|---|
| No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | |
| ||||||||
| Low | 19 | 7.0% (4.3%‐10.7%) | 61 | 5.4% (4.2%‐6.9%) | 1,180 | 8.2% (7.8%‐8.7%) | 2,279 | 15.2%b (14.6%‐15.7%) |
| Medium | 65 | 23.9% (19.0%‐29.4%) | 235 | 21.0% (18.6%‐23.5%) | 6,503 | 45.2%b (44.4%‐46.0%) | 7,803 | 51.9%b (51.1%‐52.7%) |
| High | 188 | 69.1% (63.3%‐74.6%) | 824 | 73.6% (70.9%‐76.1%) | 6,703 | 46.6%b (45.8%‐47.4%) | 4,957 | 33.0%b (32.2%‐33.7%) |
| Death | 137 | 50.4% (44.3%‐56.5%) | 645 | 57.6%c (54.6%‐60.5%) | 4,186 | 29.1%b (28.4%‐29.8%) | 2,744 | 18.2%b (17.6%‐18.9%) |
There were no significant differences in the percentage of hospitalist cases in which payment was made (32.0%; 95% CI: 26.5%‐37.9%) compared to any of the other 3 groups studied (Table 5). The median payment in hospitalist cases, $240,000 (interquartile range [IQR]: $100,000$524,245), was significantly higher than that in all other inpatient cases ($156,714; IQR: $39,188$488,996) (P=0.040) and in outpatient cases ($92,671; IQR: $20,895$325,461) (P<0.001), though not significantly different than the median payment in all other inpatient internal medicine cases ($206,314; IQR: $57,382$488,996).
| Hospitalist Cases, Internal Medicine Only | All Other Inpatient Internal Medicine Cases | All Other Inpatient Cases | Outpatient Cases | |||||
|---|---|---|---|---|---|---|---|---|
| No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | No. of Cases | % of Cases (95% CI) | |
| ||||||||
| Payment made | 87 | 32.0% (26.5%‐37.9%) | 330 | 29.5% (26.8%‐32.2%) | 5164 | 35.9% (35.1%‐36.7%) | 4632 | 30.8% (30.1%‐31.5%) |
| No payment made | 185 | 68.0% (62.1%‐73.5%) | 790 | 70.5% (67.8%‐73.2%) | 9222 | 64.1% (63.3%‐64.9%) | 10407 | 69.2% (68.5%‐69.9%) |
| Mean payment (95% CI) | $384,617 ($289,662‐$479,573) | $451,713 ($359,656‐$543,769) | $482,963 ($452,725‐$513,202) | $305,462b ($286,517‐$324,408) | ||||
| Median payment (IQR) | $240,000 ($100,000$524,245) | $206,314 ($57,382$488,996) | $156,714c ($39,188$488,996) | $92,671b ($20,895$325,461) | ||||
| Standard deviation | $445,531 | $850,086 | $1,108,404 | $657,707 | ||||
DISCUSSION
In our analysis of closed medical malpractice claims, we found that hospitalists have a significantly lower rate of claims compared to the other types of physicians studied, including other internal medicine physicians and emergency medicine physicians. Although hospitalists had a relatively low rate of claims, the severity of injury involved in those claims was high.
Prior research has found that the proportion of internal medicine physicians who face a malpractice claim each year is between 7% and 8%.[10] The rate of claims against internal medicine physicians in this prior study was similar to that of emergency medicine physicians, who, like hospitalists, are defined by their site of practice. In addition, both frequently work with acutely ill patients with whom they do not have a longitudinal relationship. However, this prior analysis did not assess for any difference in malpractice risk based on whether internal medicine physicians were practicing primarily as outpatient physicians or as hospitalists, and so the liability risk of hospitalists (as opposed to internal medicine physicians generally) remains undefined. Our analysis sought to determine whether there is a difference in claims rates when adopting a hospitalist model.
Notably, two factors have been raised as potentially increasing the risk that hospitalists will be subject to malpractice claims. The first is that hospitalists have only a brief relationship with their patients, thus limiting their ability to form the strong physician‐patient relationships that decrease the likelihood of a malpractice claim.[14, 15, 16, 17] Second, hospitalists face the challenge of transitions of care as patients move from the outpatient to the inpatient setting, and vice versa.[4, 7, 18, 19] Despite these theoretical concerns, we found that hospitalists face a relatively low rate of claims compared to other physicians. The reasons for this low liability risk remain uncertain.
One possible explanation for this relatively low rate of claims against hospitalists is that hospitalists are actually at lower risk of missing a diagnosis, the most common reason for a malpractice claim in the ambulatory setting.[20, 21, 22] In contrast to how patients may present in the clinic or the emergency department, when patients are admitted to the hospital, it is likely that they present to the hospitalist with a known problem, rather than a clinical symptom without an etiology. For example, when a patient is admitted to the hospital for chest pain, other physicians may have already been concerned enough to raise clinical suspicion of a myocardial infarction and order basic testing, making the diagnosis less likely to be missed when the hospitalist assumes care of that patient. Indeed, we found that, among the claims made against hospitalists, the leading type of allegation was an error in treatment rather than an error in diagnosis.
It is also possible that the lower rate of claims against hospitalists reflects the high quality of care provided by hospitalists, resulting from their clinical expertise and knowledge of hospital systems. High clinical volume is associated with better outcomes for multiple surgical procedures,[23] and, to a lesser degree, for certain medical conditions.[24] Because hospitalists are likely to see a high volume of those medical conditions that regularly require admission to an inpatient medical service, this high volume could translate into higher quality of care, both because of medical expertise in managing these conditions and because of proficiency in dealing with hospital systems. However, this theory must be tempered by the conclusion from earlier work that did not show a large difference in outcomes among patients cared for by hospitalists.[25]
Another reason for the lower claims rate could be a direct result of how hospitalist jobs are structured. In prior research, an inadequate physician‐patient relationship has been found to be a factor in patients deciding to file a malpractice claim.[14, 15, 16, 17] Although hospitalists usually only care for their patients during the few days of the hospital admission, hospitalists are on site all day and thus are able to frequently communicate with patients and families face to face. This level of interaction may allow for a sufficiently healthy, even if time‐limited, physician‐patient relationship that meets patients' expectations.
For the claims that occur, deficiencies in communication and transitions of care, both of which have been cited as a special concern for hospitalists, were in fact present in 37.9% of the hospitalist cases we evaluated.[7] This proportion appears to be higher than previous work in the ambulatory setting that showed communication generally to be a factor in 30% of cases, and problems related to handoffs specifically to be a factor in 20% of cases.[20] These findings highlight the risks associated with the discontinuities inherent in the hospitalist model, which can occur on admission, during the hospitalization (where a number of hospitalists may care for one patient), and on discharge. These findings also point to the need for ongoing efforts to address these concerns.
More than half of the claims against hospitalists (50.4%; 95% CI: 44.3%‐56.5%) involved the death of the patient. However, this high rate of claims involving the death of the patient did not appear to be specific to hospitalists. Rather, this appeared to be true for inpatient internal medicine cases generally, because the rate of claims in which the severity of injury was death was significantly higher among nonhospitalist inpatient internal medicine cases (57.6%; 95% CI: 54.6%‐60.5%).
Our study has several limitations. Though the database that we used includes hospitals and physician groups from 20 different liability carriers covering multiple regions across the country, it nonetheless may not be entirely representative, especially given the variation in the hospitalist models used at different institutions (for example, coverage of intensive care unit patients) and because of geographic variability. However, the sample did contain a large proportion (approximately 30%) of closed claims nationally. Claims rates are based on data from a single insurance carrier, albeit one with 23,847 PCYs among internal medicine physicians during the study period. Second, we defined hospitalist cases as those cases in which the hospitalist was the attending of record at the time of the clinical event that gave rise to the malpractice claim. It is possible that this definition captured claims in which the hospitalist, although the attending of record, may not have been directly involved in the care leading to the claim (for example, a problem with a surgery gave rise to the claim). Third, we assessed liability risk by years covered, which does not account for risk that may vary based on clinical volume.
Overall, our results suggest that liability fears should not impede the adoption of the hospitalist model in internal medicine. Not only do hospitalists have a lower rate of claims, but there is also no difference in the rate at which claims are paid or mean indemnity amounts for the claims that are paid for hospitalists. Previous analyses of the costs associated with care by hospitalists, compared to care by other types of physicians, have not taken into account the decreased liability costs that are likely associated with care provided by hospitalists.[25, 26]
In conclusion, contrary to concerns that have been raised, we found that hospitalists face a lower rate of malpractice claims when compared to other internal medicine physicians and specialties. However, we did find that care discontinuities may be resulting in liability risk due to communication and handoff‐related errors. Improvements in the hospitalist model of care targeted at improving communication and clinical judgment may not only further reduce claims against hospitalists, but also improve the safety of care associated with this model.
Disclosures
Dr. Kachalia has received honoraria from Quantia MD for presentations on patient safety. Dr. Schaffer, Ms. Raman, and Ms. Puopolo have no disclosures. The authors report no conflicts of interest.
- American Hospital Association. AHA Hospital Statistics. 2012 ed. Chicago, IL: Health Forum; 2012.
- , . The emerging role of "hospitalists" in the American health care system. N Engl J Med. 1996;335(7):514–517.
- , , . Specialty hospitalists: analyzing an emerging phenomenon. JAMA. 2012;307(16):1699–1700.
- , , , . Primary care physician attitudes regarding communication with hospitalists. Am J Med. 2001;111(9B):15S–20S.
- . Hospitalists and the doctor‐patient relationship. J Legal Stud. 2001;30(2):589–606.
- . Rapport and the hospitalist. Am J Med. 2001;111(9B):31S–35S.
- . Key legal principles for hospitalists. Am J Med. 2001;111(9B):5S–9S.
- , . Medical malpractice. In: McKean S, Ross J, Dressler D, Brotman D, Ginsberg J, eds. Principles and Practice of Hospital Medicine. New York, NY: McGraw Hill; 2012.
- , , . Paid malpractice claims for adverse events in inpatient and outpatient settings. JAMA. 2011;305(23):2427–2431.
- , , , . Malpractice risk according to physician specialty. N Engl J Med. 2011;365(7):629–636.
- Sowka MP, ed. NAIC Malpractice Claims, Final Compilation. Brookfield, WI: National Association of Insurance Commissioners; 1980.
- , . Medical Malpractice Insurance Claims in Seven States, 2000–2004. U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics Special Report; March 2007.
- Bureau of Labor Statistics. Available at: http://data.bls.gov/pdq/querytool.jsp?survey=cu. Accessed December 3, 2012.
- , , , . The doctor‐patient relationship and malpractice. Lessons from plaintiff depositions. Arch Intern Med. 1994;154(12):1365–1370.
- , , , . Factors that prompted families to file medical malpractice claims following perinatal injuries. JAMA. 1992;267(10):1359–1363.
- , , . Why do people sue doctors? A study of patients and relatives taking legal action. Lancet. 1994;343(8913):1609–1613.
- , , , , . Physician‐patient communication. The relationship with malpractice claims among primary care physicians and surgeons. JAMA. 1997;277(7):553–559.
- , , , . Medical errors related to discontinuity of care from an inpatient to an outpatient setting. J Gen Intern Med. 2003;18(8):646–651.
- , . The ethics of the hospitalist model. J Hosp Med. 2010;5(3):183–188.
- , , , et al. Missed and delayed diagnoses in the ambulatory setting: a study of closed malpractice claims. Ann Intern Med. 2006;145(7):488–496.
- , , , , , . Learning from malpractice claims about negligent, adverse events in primary care in the United States. Qual Saf Health Care. 2004;13(2):121–126.
- , , , et al. Primary care closed claims experience of Massachusetts malpractice insurers. JAMA Intern Med. 2013;173(22):2063–2068.
- , , , et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–1137.
- , , , et al. Hospital volume and 30‐day mortality for three common medical conditions. N Engl J Med. 2010;362(12):1110–1118.
- , , , , , . Outcomes of care by hospitalists, general internists, and family physicians. N Engl J Med. 2007;357(25):2589–2600.
- , , , et al. Quality of care for decompensated heart failure: comparable performance between academic hospitalists and non‐hospitalists. J Gen Intern Med. 2008;23(9):1399–1406.
- American Hospital Association. AHA Hospital Statistics. 2012 ed. Chicago, IL: Health Forum; 2012.
- , . The emerging role of "hospitalists" in the American health care system. N Engl J Med. 1996;335(7):514–517.
- , , . Specialty hospitalists: analyzing an emerging phenomenon. JAMA. 2012;307(16):1699–1700.
- , , , . Primary care physician attitudes regarding communication with hospitalists. Am J Med. 2001;111(9B):15S–20S.
- . Hospitalists and the doctor‐patient relationship. J Legal Stud. 2001;30(2):589–606.
- . Rapport and the hospitalist. Am J Med. 2001;111(9B):31S–35S.
- . Key legal principles for hospitalists. Am J Med. 2001;111(9B):5S–9S.
- , . Medical malpractice. In: McKean S, Ross J, Dressler D, Brotman D, Ginsberg J, eds. Principles and Practice of Hospital Medicine. New York, NY: McGraw Hill; 2012.
- , , . Paid malpractice claims for adverse events in inpatient and outpatient settings. JAMA. 2011;305(23):2427–2431.
- , , , . Malpractice risk according to physician specialty. N Engl J Med. 2011;365(7):629–636.
- Sowka MP, ed. NAIC Malpractice Claims, Final Compilation. Brookfield, WI: National Association of Insurance Commissioners; 1980.
- , . Medical Malpractice Insurance Claims in Seven States, 2000–2004. U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics Special Report; March 2007.
- Bureau of Labor Statistics. Available at: http://data.bls.gov/pdq/querytool.jsp?survey=cu. Accessed December 3, 2012.
- , , , . The doctor‐patient relationship and malpractice. Lessons from plaintiff depositions. Arch Intern Med. 1994;154(12):1365–1370.
- , , , . Factors that prompted families to file medical malpractice claims following perinatal injuries. JAMA. 1992;267(10):1359–1363.
- , , . Why do people sue doctors? A study of patients and relatives taking legal action. Lancet. 1994;343(8913):1609–1613.
- , , , , . Physician‐patient communication. The relationship with malpractice claims among primary care physicians and surgeons. JAMA. 1997;277(7):553–559.
- , , , . Medical errors related to discontinuity of care from an inpatient to an outpatient setting. J Gen Intern Med. 2003;18(8):646–651.
- , . The ethics of the hospitalist model. J Hosp Med. 2010;5(3):183–188.
- , , , et al. Missed and delayed diagnoses in the ambulatory setting: a study of closed malpractice claims. Ann Intern Med. 2006;145(7):488–496.
- , , , , , . Learning from malpractice claims about negligent, adverse events in primary care in the United States. Qual Saf Health Care. 2004;13(2):121–126.
- , , , et al. Primary care closed claims experience of Massachusetts malpractice insurers. JAMA Intern Med. 2013;173(22):2063–2068.
- , , , et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–1137.
- , , , et al. Hospital volume and 30‐day mortality for three common medical conditions. N Engl J Med. 2010;362(12):1110–1118.
- , , , , , . Outcomes of care by hospitalists, general internists, and family physicians. N Engl J Med. 2007;357(25):2589–2600.
- , , , et al. Quality of care for decompensated heart failure: comparable performance between academic hospitalists and non‐hospitalists. J Gen Intern Med. 2008;23(9):1399–1406.
© 2014 Society of Hospital Medicine
Fillers for men
Idealized masculine facial features tend to include an overhanging, horizontal brow with minimal arch, deeper-set eyes that look closer together, a somewhat larger nose, a wider mouth, a squared lower face, and a beard or coarser texture to the lower facial skin. A major component of aesthetic disharmony in the aging face in both men and women, however, is the loss or redistribution of subcutaneous fat. Detailed studies by Rohrich and Pessa have demonstrated that facial fat (unlike fat elsewhere in the body) is partitioned into discrete compartments that may age independently of one another. Redistribution and loss of these fat pads contribute to formation of the nasojugal fold, malar crease, nasolabial fold, prejowl sulcus and marionette lines, as well as wasting of the temples, superior brow, and buccal fat. These changes can be visualized most strikingly in cases of cachexia and severe HIV-associated lipodystrophy.
When using fillers to restore volume loss and wrinkles in men, care must be taken to not overfeminize the male face. Filler placement in the anteromedial cheek, submalar cheek, temples, tear trough area, nasolabial folds, and marionette areas are often similar to filler placement in women if the patient has an issue with volume loss in those areas. The main difference is placement in the zygomaticomalar region of the cheek (or the point where the maximal light reflection is off of the highest point of the zygoma, or cheek bone) and the lips. Care must be taken not to overvolumize this region in men.
Also, even within ethnic groups, the male lip is typically not as tall and curvy as the female lip; it often appears less full, with more of a shadow cast by the lower lip.
Men tend to prefer treatments with less downtime and more natural results and are less risk tolerant than women are. Keeping these points in mind can increase patient satisfaction when offering fillers to male patients.
Source: Rohrich R., Pessa J. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. J. Plast. Reconstr. Surg. 2007;119:2219-27.
Dr. Talakoub and Dr. Wesley are co-contributors to a monthly Aesthetic Dermatology column in Skin & Allergy News. Dr. Talakoub is in private practice in McLean, Va. Dr. Wesley practices dermatology in Beverly Hills, Calif. This month’s column is by Dr. Wesley.
Idealized masculine facial features tend to include an overhanging, horizontal brow with minimal arch, deeper-set eyes that look closer together, a somewhat larger nose, a wider mouth, a squared lower face, and a beard or coarser texture to the lower facial skin. A major component of aesthetic disharmony in the aging face in both men and women, however, is the loss or redistribution of subcutaneous fat. Detailed studies by Rohrich and Pessa have demonstrated that facial fat (unlike fat elsewhere in the body) is partitioned into discrete compartments that may age independently of one another. Redistribution and loss of these fat pads contribute to formation of the nasojugal fold, malar crease, nasolabial fold, prejowl sulcus and marionette lines, as well as wasting of the temples, superior brow, and buccal fat. These changes can be visualized most strikingly in cases of cachexia and severe HIV-associated lipodystrophy.
When using fillers to restore volume loss and wrinkles in men, care must be taken to not overfeminize the male face. Filler placement in the anteromedial cheek, submalar cheek, temples, tear trough area, nasolabial folds, and marionette areas are often similar to filler placement in women if the patient has an issue with volume loss in those areas. The main difference is placement in the zygomaticomalar region of the cheek (or the point where the maximal light reflection is off of the highest point of the zygoma, or cheek bone) and the lips. Care must be taken not to overvolumize this region in men.
Also, even within ethnic groups, the male lip is typically not as tall and curvy as the female lip; it often appears less full, with more of a shadow cast by the lower lip.
Men tend to prefer treatments with less downtime and more natural results and are less risk tolerant than women are. Keeping these points in mind can increase patient satisfaction when offering fillers to male patients.
Source: Rohrich R., Pessa J. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. J. Plast. Reconstr. Surg. 2007;119:2219-27.
Dr. Talakoub and Dr. Wesley are co-contributors to a monthly Aesthetic Dermatology column in Skin & Allergy News. Dr. Talakoub is in private practice in McLean, Va. Dr. Wesley practices dermatology in Beverly Hills, Calif. This month’s column is by Dr. Wesley.
Idealized masculine facial features tend to include an overhanging, horizontal brow with minimal arch, deeper-set eyes that look closer together, a somewhat larger nose, a wider mouth, a squared lower face, and a beard or coarser texture to the lower facial skin. A major component of aesthetic disharmony in the aging face in both men and women, however, is the loss or redistribution of subcutaneous fat. Detailed studies by Rohrich and Pessa have demonstrated that facial fat (unlike fat elsewhere in the body) is partitioned into discrete compartments that may age independently of one another. Redistribution and loss of these fat pads contribute to formation of the nasojugal fold, malar crease, nasolabial fold, prejowl sulcus and marionette lines, as well as wasting of the temples, superior brow, and buccal fat. These changes can be visualized most strikingly in cases of cachexia and severe HIV-associated lipodystrophy.
When using fillers to restore volume loss and wrinkles in men, care must be taken to not overfeminize the male face. Filler placement in the anteromedial cheek, submalar cheek, temples, tear trough area, nasolabial folds, and marionette areas are often similar to filler placement in women if the patient has an issue with volume loss in those areas. The main difference is placement in the zygomaticomalar region of the cheek (or the point where the maximal light reflection is off of the highest point of the zygoma, or cheek bone) and the lips. Care must be taken not to overvolumize this region in men.
Also, even within ethnic groups, the male lip is typically not as tall and curvy as the female lip; it often appears less full, with more of a shadow cast by the lower lip.
Men tend to prefer treatments with less downtime and more natural results and are less risk tolerant than women are. Keeping these points in mind can increase patient satisfaction when offering fillers to male patients.
Source: Rohrich R., Pessa J. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. J. Plast. Reconstr. Surg. 2007;119:2219-27.
Dr. Talakoub and Dr. Wesley are co-contributors to a monthly Aesthetic Dermatology column in Skin & Allergy News. Dr. Talakoub is in private practice in McLean, Va. Dr. Wesley practices dermatology in Beverly Hills, Calif. This month’s column is by Dr. Wesley.
Advanced practice registered nurses in cardiology
In case you didn’t notice, our clinical practice has been reinforced by a entirely new class of performers who have become essential to our daily activities.
They are Advanced Practice Registered Nurses, whose role has evolved over the last 50 years from the Coronary Care Unit nurse with special training in coronary care to an array of well-trained women and men who have received both Bachelor’s and Master’s degrees in Nursing.
As a further extension of their training, many are now going on to achieve a further doctorate degree in nursing after 90 hours of postgraduate classes at certified academic centers and additional clinical experience in a variety of fields, including cardiology. The nurses completing those programs will be certified and licensed as APRNs. They come to our practice with remarkable experience and expertise in arrhythmia and heart failure management, as well as interventional skills, on top of wide experience in the management of patients in critical care units. Their integration into comprehensive and collaborative cardiac care raises challenges to and opportunities for the cardiologist.
A recent survey of large cardiology clinics initiated by the Summit Medical Group assessed the role of the APRN in the care of patients both in hospitals and in clinics. It reported that in many of cardiology clinics surveyed, APRNs provide an expanding role in patient care leading to variable relationships between the patient and the cardiologist. In some settings, the APRNs often function independent of physician interaction, initiating the patients’ entrance into the clinic and managing their follow-up. In other situations, they may be supervised by a cardiologist and their future laboratory studies and therapy are completely managed by the APRN, who functions as a professional associate of a physician. However, in many situations the cardiologist may have little or no contact with the patient.
While the APRN is seeing the patient, the cardiologists often are seeing their own patients or, more likely, are involved with maintaining the electronic medical record or performing or interpreting tests that are usually reimbursed at a fee that is a multiple of that received for a patient visit alone. Much of this is carried out under the heading of “coordinated care” and is managed in a multidisciplinary matrix in which many specialists and APRNs play a role in the care of the patient. In this setting, the doctor has become manager of a diverse group of support staff, including APRNs, and may be increasingly remote from direct patient care. My medical colleagues find the process as a way to increase the patient “pass through.” Many patients presume that the APRN is a reasonable alternative to a busy cardiologist or are interacting with their cardiologist.
As doctors, we are divesting ourselves from the one thing that sets us apart and makes us unique in the health care system; the ability to interact with patients in a comprehensive way. We seem to be on the slippery slope to medical obsolescence, soon to be replaced by staff who can triage our patients to the next appropriate test. Both the patient and doctor seem to have slipped into a Walmart-like world where expedience dominates over skill and shortcuts are the alternative to thoughtful personal physician-patient interaction.
Dr. Goldstein, medical editor of Cardiology News, is professor of medicine at Wayne State University and division head emeritus of cardiovascular medicine at Henry Ford Hospital, both in Detroit. He is on data safety monitoring committees for the National Institutes of Health and several pharmaceutical companies.
In case you didn’t notice, our clinical practice has been reinforced by a entirely new class of performers who have become essential to our daily activities.
They are Advanced Practice Registered Nurses, whose role has evolved over the last 50 years from the Coronary Care Unit nurse with special training in coronary care to an array of well-trained women and men who have received both Bachelor’s and Master’s degrees in Nursing.
As a further extension of their training, many are now going on to achieve a further doctorate degree in nursing after 90 hours of postgraduate classes at certified academic centers and additional clinical experience in a variety of fields, including cardiology. The nurses completing those programs will be certified and licensed as APRNs. They come to our practice with remarkable experience and expertise in arrhythmia and heart failure management, as well as interventional skills, on top of wide experience in the management of patients in critical care units. Their integration into comprehensive and collaborative cardiac care raises challenges to and opportunities for the cardiologist.
A recent survey of large cardiology clinics initiated by the Summit Medical Group assessed the role of the APRN in the care of patients both in hospitals and in clinics. It reported that in many of cardiology clinics surveyed, APRNs provide an expanding role in patient care leading to variable relationships between the patient and the cardiologist. In some settings, the APRNs often function independent of physician interaction, initiating the patients’ entrance into the clinic and managing their follow-up. In other situations, they may be supervised by a cardiologist and their future laboratory studies and therapy are completely managed by the APRN, who functions as a professional associate of a physician. However, in many situations the cardiologist may have little or no contact with the patient.
While the APRN is seeing the patient, the cardiologists often are seeing their own patients or, more likely, are involved with maintaining the electronic medical record or performing or interpreting tests that are usually reimbursed at a fee that is a multiple of that received for a patient visit alone. Much of this is carried out under the heading of “coordinated care” and is managed in a multidisciplinary matrix in which many specialists and APRNs play a role in the care of the patient. In this setting, the doctor has become manager of a diverse group of support staff, including APRNs, and may be increasingly remote from direct patient care. My medical colleagues find the process as a way to increase the patient “pass through.” Many patients presume that the APRN is a reasonable alternative to a busy cardiologist or are interacting with their cardiologist.
As doctors, we are divesting ourselves from the one thing that sets us apart and makes us unique in the health care system; the ability to interact with patients in a comprehensive way. We seem to be on the slippery slope to medical obsolescence, soon to be replaced by staff who can triage our patients to the next appropriate test. Both the patient and doctor seem to have slipped into a Walmart-like world where expedience dominates over skill and shortcuts are the alternative to thoughtful personal physician-patient interaction.
Dr. Goldstein, medical editor of Cardiology News, is professor of medicine at Wayne State University and division head emeritus of cardiovascular medicine at Henry Ford Hospital, both in Detroit. He is on data safety monitoring committees for the National Institutes of Health and several pharmaceutical companies.
In case you didn’t notice, our clinical practice has been reinforced by a entirely new class of performers who have become essential to our daily activities.
They are Advanced Practice Registered Nurses, whose role has evolved over the last 50 years from the Coronary Care Unit nurse with special training in coronary care to an array of well-trained women and men who have received both Bachelor’s and Master’s degrees in Nursing.
As a further extension of their training, many are now going on to achieve a further doctorate degree in nursing after 90 hours of postgraduate classes at certified academic centers and additional clinical experience in a variety of fields, including cardiology. The nurses completing those programs will be certified and licensed as APRNs. They come to our practice with remarkable experience and expertise in arrhythmia and heart failure management, as well as interventional skills, on top of wide experience in the management of patients in critical care units. Their integration into comprehensive and collaborative cardiac care raises challenges to and opportunities for the cardiologist.
A recent survey of large cardiology clinics initiated by the Summit Medical Group assessed the role of the APRN in the care of patients both in hospitals and in clinics. It reported that in many of cardiology clinics surveyed, APRNs provide an expanding role in patient care leading to variable relationships between the patient and the cardiologist. In some settings, the APRNs often function independent of physician interaction, initiating the patients’ entrance into the clinic and managing their follow-up. In other situations, they may be supervised by a cardiologist and their future laboratory studies and therapy are completely managed by the APRN, who functions as a professional associate of a physician. However, in many situations the cardiologist may have little or no contact with the patient.
While the APRN is seeing the patient, the cardiologists often are seeing their own patients or, more likely, are involved with maintaining the electronic medical record or performing or interpreting tests that are usually reimbursed at a fee that is a multiple of that received for a patient visit alone. Much of this is carried out under the heading of “coordinated care” and is managed in a multidisciplinary matrix in which many specialists and APRNs play a role in the care of the patient. In this setting, the doctor has become manager of a diverse group of support staff, including APRNs, and may be increasingly remote from direct patient care. My medical colleagues find the process as a way to increase the patient “pass through.” Many patients presume that the APRN is a reasonable alternative to a busy cardiologist or are interacting with their cardiologist.
As doctors, we are divesting ourselves from the one thing that sets us apart and makes us unique in the health care system; the ability to interact with patients in a comprehensive way. We seem to be on the slippery slope to medical obsolescence, soon to be replaced by staff who can triage our patients to the next appropriate test. Both the patient and doctor seem to have slipped into a Walmart-like world where expedience dominates over skill and shortcuts are the alternative to thoughtful personal physician-patient interaction.
Dr. Goldstein, medical editor of Cardiology News, is professor of medicine at Wayne State University and division head emeritus of cardiovascular medicine at Henry Ford Hospital, both in Detroit. He is on data safety monitoring committees for the National Institutes of Health and several pharmaceutical companies.
Bioengineered Brain Tissue: A Research Breakthrough
Bioengineers at Tufts University in Boston, Massachusetts have created 3-dimensional (3D), functional brainlike tissue that can be kept alive in a laboratory for more than 2 months. It is a major research achievement that promises to advance research into brain injury and disease.
The tissue was developed at the Tufts Tissue Engineering Resource Center, which is funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The researchers generated the brainlike tissue by creating a novel composite structure of 2 biomaterials: a spongy scaffold of silk protein that neurons can attach to and a softer, collagen-based gel to encourage axon growth.
The 3D aspect of the new tissue represents a step beyond the current research situation, in which scientists grow neurons in petri dishes. Neurons grown that way can’t duplicate the compartmentalization of gray and white matter in the brain, which is critical to research into brain injuries and diseases that affect those areas differently. Moreover, attempts to grow neurons in 3D gel environments have produced tissue models that don’t allow for tissue-level function, according to a NIBIB release. By contrast, neurons in the 3D tissue act more like those seen in a rat brain, with similar electrical activity and responsiveness to stimuli such as neurotoxins. The gel-based neurons begin to deteriorate within 24 hours.
The longevity and functionality of the new tissue allow researchers to track tissue response and repair in real time, over longer periods. David Kaplan, PhD, director of the Tufts Tissue Engineering Resource Center and lead investigator, said, “The fact that we can maintain this tissue for months in the lab means we can start to look at neurological diseases in ways that you can’t otherwise because you need long timeframes to study some of the key brain diseases.”
The discovery could bring new treatments for veterans with brain injuries. In early experiments, the researchers studied chemical and electrical changes that immediately follow traumatic brain injury and changes in the brain as it responds to a drug. Calling the work “an exceptional feat,” Rosemarie Hunziker, PhD, program director of Tissue Engineering at NIBIB, said, “The hope is that use of this model could lead to an acceleration of therapies for brain dysfunction.”
Bioengineers at Tufts University in Boston, Massachusetts have created 3-dimensional (3D), functional brainlike tissue that can be kept alive in a laboratory for more than 2 months. It is a major research achievement that promises to advance research into brain injury and disease.
The tissue was developed at the Tufts Tissue Engineering Resource Center, which is funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The researchers generated the brainlike tissue by creating a novel composite structure of 2 biomaterials: a spongy scaffold of silk protein that neurons can attach to and a softer, collagen-based gel to encourage axon growth.
The 3D aspect of the new tissue represents a step beyond the current research situation, in which scientists grow neurons in petri dishes. Neurons grown that way can’t duplicate the compartmentalization of gray and white matter in the brain, which is critical to research into brain injuries and diseases that affect those areas differently. Moreover, attempts to grow neurons in 3D gel environments have produced tissue models that don’t allow for tissue-level function, according to a NIBIB release. By contrast, neurons in the 3D tissue act more like those seen in a rat brain, with similar electrical activity and responsiveness to stimuli such as neurotoxins. The gel-based neurons begin to deteriorate within 24 hours.
The longevity and functionality of the new tissue allow researchers to track tissue response and repair in real time, over longer periods. David Kaplan, PhD, director of the Tufts Tissue Engineering Resource Center and lead investigator, said, “The fact that we can maintain this tissue for months in the lab means we can start to look at neurological diseases in ways that you can’t otherwise because you need long timeframes to study some of the key brain diseases.”
The discovery could bring new treatments for veterans with brain injuries. In early experiments, the researchers studied chemical and electrical changes that immediately follow traumatic brain injury and changes in the brain as it responds to a drug. Calling the work “an exceptional feat,” Rosemarie Hunziker, PhD, program director of Tissue Engineering at NIBIB, said, “The hope is that use of this model could lead to an acceleration of therapies for brain dysfunction.”
Bioengineers at Tufts University in Boston, Massachusetts have created 3-dimensional (3D), functional brainlike tissue that can be kept alive in a laboratory for more than 2 months. It is a major research achievement that promises to advance research into brain injury and disease.
The tissue was developed at the Tufts Tissue Engineering Resource Center, which is funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The researchers generated the brainlike tissue by creating a novel composite structure of 2 biomaterials: a spongy scaffold of silk protein that neurons can attach to and a softer, collagen-based gel to encourage axon growth.
The 3D aspect of the new tissue represents a step beyond the current research situation, in which scientists grow neurons in petri dishes. Neurons grown that way can’t duplicate the compartmentalization of gray and white matter in the brain, which is critical to research into brain injuries and diseases that affect those areas differently. Moreover, attempts to grow neurons in 3D gel environments have produced tissue models that don’t allow for tissue-level function, according to a NIBIB release. By contrast, neurons in the 3D tissue act more like those seen in a rat brain, with similar electrical activity and responsiveness to stimuli such as neurotoxins. The gel-based neurons begin to deteriorate within 24 hours.
The longevity and functionality of the new tissue allow researchers to track tissue response and repair in real time, over longer periods. David Kaplan, PhD, director of the Tufts Tissue Engineering Resource Center and lead investigator, said, “The fact that we can maintain this tissue for months in the lab means we can start to look at neurological diseases in ways that you can’t otherwise because you need long timeframes to study some of the key brain diseases.”
The discovery could bring new treatments for veterans with brain injuries. In early experiments, the researchers studied chemical and electrical changes that immediately follow traumatic brain injury and changes in the brain as it responds to a drug. Calling the work “an exceptional feat,” Rosemarie Hunziker, PhD, program director of Tissue Engineering at NIBIB, said, “The hope is that use of this model could lead to an acceleration of therapies for brain dysfunction.”
Megakaryocytes can control HSCs, team finds
to a megakaryocyte (red)
Credit: Meng Zhao
For the first time, researchers have shown that hematopoietic stem cells (HSCs) can be directly controlled by their own progeny, megakaryocytes.
Preclinical experiments revealed that megakaryocytes maintain HSC quiescence during homeostasis and promote HSC regeneration after chemotherapeutic stress.
The discovery suggests megakaryocytes might be used to treat patients with low blood cell counts and to expand HSCs for transplant.
The researchers described these findings in Nature Medicine.
The team examined the relationship between megakaryocytes and HSCs in mouse bone marrow. And they discovered that, as a terminally differentiated progeny, megakaryocytes regulate HSCs by performing two previously unknown functions.
“Megakaryocytes can directly regulate the amount of hematopoietic stem cells by telling the cells when they need to keep in the quiescent stage and when they need to start proliferating to meet increased demand,” said study author Meng Zhao, PhD, of the Stowers Institute for Medical Research in Kansas City, Missouri.
The researchers found that the protein transforming growth factor B1 (TGF-B1), contained in megakaryocytes, signaled quiescence.
And, when under stress from chemotherapy, megakaryocytes signaled fibroblast growth factor 1 (FGF1), to stimulate HSC proliferation.
“Our findings suggest that megakaryocytes are required for the recovery of hematopoietic stem cells post-chemotherapy,” said Linheng Li, PhD, also of the Stowers Institute.
The discovery could provide insight for using megakaryocyte-derived factors, such as TGF-B1 and FGF1, clinically to facilitate the regeneration of HSCs, he added.
Engineering a megakaryocyte niche that supports the growth of HSCs in culture is the next step for the researchers. They are also investigating whether a megakaryocyte niche can be used to help expand human HSCs in vitro for transplant.
These findings are supported by similar research also reported in Nature Medicine.
to a megakaryocyte (red)
Credit: Meng Zhao
For the first time, researchers have shown that hematopoietic stem cells (HSCs) can be directly controlled by their own progeny, megakaryocytes.
Preclinical experiments revealed that megakaryocytes maintain HSC quiescence during homeostasis and promote HSC regeneration after chemotherapeutic stress.
The discovery suggests megakaryocytes might be used to treat patients with low blood cell counts and to expand HSCs for transplant.
The researchers described these findings in Nature Medicine.
The team examined the relationship between megakaryocytes and HSCs in mouse bone marrow. And they discovered that, as a terminally differentiated progeny, megakaryocytes regulate HSCs by performing two previously unknown functions.
“Megakaryocytes can directly regulate the amount of hematopoietic stem cells by telling the cells when they need to keep in the quiescent stage and when they need to start proliferating to meet increased demand,” said study author Meng Zhao, PhD, of the Stowers Institute for Medical Research in Kansas City, Missouri.
The researchers found that the protein transforming growth factor B1 (TGF-B1), contained in megakaryocytes, signaled quiescence.
And, when under stress from chemotherapy, megakaryocytes signaled fibroblast growth factor 1 (FGF1), to stimulate HSC proliferation.
“Our findings suggest that megakaryocytes are required for the recovery of hematopoietic stem cells post-chemotherapy,” said Linheng Li, PhD, also of the Stowers Institute.
The discovery could provide insight for using megakaryocyte-derived factors, such as TGF-B1 and FGF1, clinically to facilitate the regeneration of HSCs, he added.
Engineering a megakaryocyte niche that supports the growth of HSCs in culture is the next step for the researchers. They are also investigating whether a megakaryocyte niche can be used to help expand human HSCs in vitro for transplant.
These findings are supported by similar research also reported in Nature Medicine.
to a megakaryocyte (red)
Credit: Meng Zhao
For the first time, researchers have shown that hematopoietic stem cells (HSCs) can be directly controlled by their own progeny, megakaryocytes.
Preclinical experiments revealed that megakaryocytes maintain HSC quiescence during homeostasis and promote HSC regeneration after chemotherapeutic stress.
The discovery suggests megakaryocytes might be used to treat patients with low blood cell counts and to expand HSCs for transplant.
The researchers described these findings in Nature Medicine.
The team examined the relationship between megakaryocytes and HSCs in mouse bone marrow. And they discovered that, as a terminally differentiated progeny, megakaryocytes regulate HSCs by performing two previously unknown functions.
“Megakaryocytes can directly regulate the amount of hematopoietic stem cells by telling the cells when they need to keep in the quiescent stage and when they need to start proliferating to meet increased demand,” said study author Meng Zhao, PhD, of the Stowers Institute for Medical Research in Kansas City, Missouri.
The researchers found that the protein transforming growth factor B1 (TGF-B1), contained in megakaryocytes, signaled quiescence.
And, when under stress from chemotherapy, megakaryocytes signaled fibroblast growth factor 1 (FGF1), to stimulate HSC proliferation.
“Our findings suggest that megakaryocytes are required for the recovery of hematopoietic stem cells post-chemotherapy,” said Linheng Li, PhD, also of the Stowers Institute.
The discovery could provide insight for using megakaryocyte-derived factors, such as TGF-B1 and FGF1, clinically to facilitate the regeneration of HSCs, he added.
Engineering a megakaryocyte niche that supports the growth of HSCs in culture is the next step for the researchers. They are also investigating whether a megakaryocyte niche can be used to help expand human HSCs in vitro for transplant.
These findings are supported by similar research also reported in Nature Medicine.
Trio-CES produces higher molecular diagnostic yield
Calvin, who was diagnosed
with Pitt-Hopkins Syndrome
via trio-CES
Credit: Lapidus family
A 3-pronged approach to clinical exome sequencing (CES) can provide a higher diagnostic yield than traditional molecular diagnostic methods, results of a new study suggest.
Investigators found that sequencing a patient’s exome together with his or her parents’—a method known as trio-CES—greatly improved the ability to reach a firm diagnosis in children with suspected genetic conditions.
This research was published in JAMA. It was released to coincide with a presentation at the American Society of Human Genetics Annual Meeting in San Diego.
The researchers performed CES on 814 patients with undiagnosed, suspected genetic conditions between January 2012 and August 2014. Sequencing was conducted as trio-CES or as proband-CES (only the affected individual sequenced) when parental samples were not available.
The team funneled the raw data through an informatics pipeline to identify variants from the standard human genome. Next, they applied a series of filters to the data based on the patient’s family history and other relevant aspects of his or her condition.
The investigators then hunted for all genes and mutations linked by medical literature to the patient’s symptoms. And a multidisciplinary team of experts reviewed the findings to reach a diagnosis.
Overall, 26% of patients (213/814) received a molecular diagnosis, with the causative variant(s) identified in a well-established clinical gene.
There was a significantly higher molecular diagnostic yield from cases performed as trio-CES relative to proband-CES—31% (127/410) and 22% (74/338), respectively.
In cases of developmental delay in children younger than 5 years (n=138), the molecular diagnosis rate was 41% (45/ 109) for trio-CES cases and 9% (2/23) for proband-CES cases.
The typical turnaround time for exome sequencing is less than 8 weeks, though test results have been returned to physicians within 10 days in medically urgent situations.
With preauthorization, many insurance providers cover the cost to sequence a child and both parents. If not, the out-of-pocket fee is about $6650.
“All families deserve a clear diagnosis of their child’s condition,” said study author Wayne Grody, MD, PhD, of the University of California, Los Angeles.
“Exome sequencing plays an important role in identifying the precise cause of a child’s illness. This is immediately useful to families and physicians in understanding how the disease occurred, preventing unnecessary testing, and developing the best strategies to treat it.”
The researchers noted, however, that the clinical implications of their findings should be better understood before trio- or proband-CES are routinely adopted.
Calvin, who was diagnosed
with Pitt-Hopkins Syndrome
via trio-CES
Credit: Lapidus family
A 3-pronged approach to clinical exome sequencing (CES) can provide a higher diagnostic yield than traditional molecular diagnostic methods, results of a new study suggest.
Investigators found that sequencing a patient’s exome together with his or her parents’—a method known as trio-CES—greatly improved the ability to reach a firm diagnosis in children with suspected genetic conditions.
This research was published in JAMA. It was released to coincide with a presentation at the American Society of Human Genetics Annual Meeting in San Diego.
The researchers performed CES on 814 patients with undiagnosed, suspected genetic conditions between January 2012 and August 2014. Sequencing was conducted as trio-CES or as proband-CES (only the affected individual sequenced) when parental samples were not available.
The team funneled the raw data through an informatics pipeline to identify variants from the standard human genome. Next, they applied a series of filters to the data based on the patient’s family history and other relevant aspects of his or her condition.
The investigators then hunted for all genes and mutations linked by medical literature to the patient’s symptoms. And a multidisciplinary team of experts reviewed the findings to reach a diagnosis.
Overall, 26% of patients (213/814) received a molecular diagnosis, with the causative variant(s) identified in a well-established clinical gene.
There was a significantly higher molecular diagnostic yield from cases performed as trio-CES relative to proband-CES—31% (127/410) and 22% (74/338), respectively.
In cases of developmental delay in children younger than 5 years (n=138), the molecular diagnosis rate was 41% (45/ 109) for trio-CES cases and 9% (2/23) for proband-CES cases.
The typical turnaround time for exome sequencing is less than 8 weeks, though test results have been returned to physicians within 10 days in medically urgent situations.
With preauthorization, many insurance providers cover the cost to sequence a child and both parents. If not, the out-of-pocket fee is about $6650.
“All families deserve a clear diagnosis of their child’s condition,” said study author Wayne Grody, MD, PhD, of the University of California, Los Angeles.
“Exome sequencing plays an important role in identifying the precise cause of a child’s illness. This is immediately useful to families and physicians in understanding how the disease occurred, preventing unnecessary testing, and developing the best strategies to treat it.”
The researchers noted, however, that the clinical implications of their findings should be better understood before trio- or proband-CES are routinely adopted.
Calvin, who was diagnosed
with Pitt-Hopkins Syndrome
via trio-CES
Credit: Lapidus family
A 3-pronged approach to clinical exome sequencing (CES) can provide a higher diagnostic yield than traditional molecular diagnostic methods, results of a new study suggest.
Investigators found that sequencing a patient’s exome together with his or her parents’—a method known as trio-CES—greatly improved the ability to reach a firm diagnosis in children with suspected genetic conditions.
This research was published in JAMA. It was released to coincide with a presentation at the American Society of Human Genetics Annual Meeting in San Diego.
The researchers performed CES on 814 patients with undiagnosed, suspected genetic conditions between January 2012 and August 2014. Sequencing was conducted as trio-CES or as proband-CES (only the affected individual sequenced) when parental samples were not available.
The team funneled the raw data through an informatics pipeline to identify variants from the standard human genome. Next, they applied a series of filters to the data based on the patient’s family history and other relevant aspects of his or her condition.
The investigators then hunted for all genes and mutations linked by medical literature to the patient’s symptoms. And a multidisciplinary team of experts reviewed the findings to reach a diagnosis.
Overall, 26% of patients (213/814) received a molecular diagnosis, with the causative variant(s) identified in a well-established clinical gene.
There was a significantly higher molecular diagnostic yield from cases performed as trio-CES relative to proband-CES—31% (127/410) and 22% (74/338), respectively.
In cases of developmental delay in children younger than 5 years (n=138), the molecular diagnosis rate was 41% (45/ 109) for trio-CES cases and 9% (2/23) for proband-CES cases.
The typical turnaround time for exome sequencing is less than 8 weeks, though test results have been returned to physicians within 10 days in medically urgent situations.
With preauthorization, many insurance providers cover the cost to sequence a child and both parents. If not, the out-of-pocket fee is about $6650.
“All families deserve a clear diagnosis of their child’s condition,” said study author Wayne Grody, MD, PhD, of the University of California, Los Angeles.
“Exome sequencing plays an important role in identifying the precise cause of a child’s illness. This is immediately useful to families and physicians in understanding how the disease occurred, preventing unnecessary testing, and developing the best strategies to treat it.”
The researchers noted, however, that the clinical implications of their findings should be better understood before trio- or proband-CES are routinely adopted.
AUDIO: Conjugated estrogen, bazedoxifene combo offers menopause treatment option
NATIONAL HARBOR, MD. – Treating menopause symptoms in women who still have a uterus can be difficult, but alternatives to estrogen are available.
For many women, the use of estrogen therapies is contraindicated – and even if it is prescribed, many women are noncompliant because of fears of increased risk of breast or uterine cancer, explained Dr. JoAnn Pinkerton of the University of Virginia, Charlottesville.
However, with the U.S. Food and Drug Administration’s recent approval of Duavee, a combination of conjugated estrogen and bazedoxifene, Dr. Pinkerton noted, women who don’t want to take estrogen have another option for quelling their menopause symptoms.
In an interview at the annual meeting of the North American Menopause Society, Dr. Pinkerton analyzes the benefits of combination therapy.
On Twitter @whitneymcknight
NATIONAL HARBOR, MD. – Treating menopause symptoms in women who still have a uterus can be difficult, but alternatives to estrogen are available.
For many women, the use of estrogen therapies is contraindicated – and even if it is prescribed, many women are noncompliant because of fears of increased risk of breast or uterine cancer, explained Dr. JoAnn Pinkerton of the University of Virginia, Charlottesville.
However, with the U.S. Food and Drug Administration’s recent approval of Duavee, a combination of conjugated estrogen and bazedoxifene, Dr. Pinkerton noted, women who don’t want to take estrogen have another option for quelling their menopause symptoms.
In an interview at the annual meeting of the North American Menopause Society, Dr. Pinkerton analyzes the benefits of combination therapy.
On Twitter @whitneymcknight
NATIONAL HARBOR, MD. – Treating menopause symptoms in women who still have a uterus can be difficult, but alternatives to estrogen are available.
For many women, the use of estrogen therapies is contraindicated – and even if it is prescribed, many women are noncompliant because of fears of increased risk of breast or uterine cancer, explained Dr. JoAnn Pinkerton of the University of Virginia, Charlottesville.
However, with the U.S. Food and Drug Administration’s recent approval of Duavee, a combination of conjugated estrogen and bazedoxifene, Dr. Pinkerton noted, women who don’t want to take estrogen have another option for quelling their menopause symptoms.
In an interview at the annual meeting of the North American Menopause Society, Dr. Pinkerton analyzes the benefits of combination therapy.
On Twitter @whitneymcknight
EXPERT ANALYSIS FROM THE NAMS ANNUAL MEETING
Exome sequencing shows potential as diagnostic tool
Credit: Graham Colm
In a large study, whole-exome sequencing provided 25% of patients with a diagnosis related to a known genetic disease, giving young
patients and their parents some long-sought answers.
The technology was able to detect a number of rare genetic events and new mutations contributing to disease.
Among the medically actionable findings were mutations related to Fanconi anemia, erythrocytosis, hemolytic anemia, and von Willebrand disease.
“The findings in this report, I believe, will forever change the future practice of pediatrics and medicine as a whole,” said study author James R. Lupski, MD, PhD, of the Baylor College of Medicine in Houston.
“It is just a matter of time before genomics moves up on the physician’s list of things to do and is ordered before formulating a differential diagnosis. It will be the new ‘family history’ that, better yet, gets you both the important variants inherited from each parent and the new mutations that contribute to disease susceptibility.”
This research was published in JAMA and is set to be presented on October 21 at the American Society of Human Genetics Annual Meeting in San Diego.
The researchers had previously conducted a pilot study of whole-exome sequencing that included 250 patients and revealed a 25% molecular diagnostic rate.
This current study included 2000 patients (88% pediatric) with clinical whole-exome sequencing analyzed between June 2012 and August 2014. The majority of patients—87.8%—had neurological disorders or a developmental delay, and 12.2% had non-neurological disorders.
The researchers collected peripheral blood, tissue, or extracted DNA samples from patients and their parents. The team sequenced patients’ DNA and compared those results to the normal reference. Any disease-associated mutations were then compared with the parent’s DNA to determine if the child inherited it from one or both parents.
In all, 504 patients (25.2%) received a molecular diagnosis, and 58% of the diagnostic mutations had not previously been reported. Two hundred and eighty patients had a single mutation that caused disease, 181 were autosomal recessive, 65 were X-linked, and 1 was presumed inherited through the mitochondria.
In 5 cases, the patient inherited 2 copies of the mutated gene from the same parent. Of the dominant mutations, 208 were de novo mutations not inherited from either parent, 32 were inherited, and 40 were not determined because parental samples were not available.
Among the de novo mutations, 5 demonstrated mosaicism, which suggested the mutation occurred after fertilization.
The researchers found 708 presumptive causative variant alleles in the 504 cases. Almost 30% of the diagnoses occurred in disease genes only identified by researchers in the last 3 years. In 65 cases, there was no available genetic test other than whole-exome sequencing to find the mutated gene at the time the test was ordered.
Twenty-three patients (about 5%) had mutations in 2 different genes, which could account for various aspects of the patient’s medical condition.
“Doctors generally try to find one diagnosis that explains all the issues a patient may have,” said study author Christine Eng, MD, of the Baylor College of Medicine.
“We have found that, in some cases, a patient may have a blended phenotype of 2 different conditions. That patients may have 2 different rare genetic diseases to explain their condition was an unexpected finding prior to the use of whole-exome sequencing.”
In the 2000 cases, incidental findings of medically actionable results that could result in early diagnosis, screening, or treatment were found in 92 patients. Three patients had more than 1 finding.
“Clinical exome sequencing can assist diagnosis in a wide range of disorders that are diagnostic dilemmas,” Dr Lupski said. “Rare variants and Mendelian disease are important contributors to disease populations. This is in sharp contrast to the thinking of population geneticists, who investigate how common variants contribute to disease susceptibility.”
“We find ‘rare variants’ in aggregate actually contribute to disease susceptibility in a big way. The individual diseases may be rare, but there are thousands of such diseases and many more being defined through genomics.”
Credit: Graham Colm
In a large study, whole-exome sequencing provided 25% of patients with a diagnosis related to a known genetic disease, giving young
patients and their parents some long-sought answers.
The technology was able to detect a number of rare genetic events and new mutations contributing to disease.
Among the medically actionable findings were mutations related to Fanconi anemia, erythrocytosis, hemolytic anemia, and von Willebrand disease.
“The findings in this report, I believe, will forever change the future practice of pediatrics and medicine as a whole,” said study author James R. Lupski, MD, PhD, of the Baylor College of Medicine in Houston.
“It is just a matter of time before genomics moves up on the physician’s list of things to do and is ordered before formulating a differential diagnosis. It will be the new ‘family history’ that, better yet, gets you both the important variants inherited from each parent and the new mutations that contribute to disease susceptibility.”
This research was published in JAMA and is set to be presented on October 21 at the American Society of Human Genetics Annual Meeting in San Diego.
The researchers had previously conducted a pilot study of whole-exome sequencing that included 250 patients and revealed a 25% molecular diagnostic rate.
This current study included 2000 patients (88% pediatric) with clinical whole-exome sequencing analyzed between June 2012 and August 2014. The majority of patients—87.8%—had neurological disorders or a developmental delay, and 12.2% had non-neurological disorders.
The researchers collected peripheral blood, tissue, or extracted DNA samples from patients and their parents. The team sequenced patients’ DNA and compared those results to the normal reference. Any disease-associated mutations were then compared with the parent’s DNA to determine if the child inherited it from one or both parents.
In all, 504 patients (25.2%) received a molecular diagnosis, and 58% of the diagnostic mutations had not previously been reported. Two hundred and eighty patients had a single mutation that caused disease, 181 were autosomal recessive, 65 were X-linked, and 1 was presumed inherited through the mitochondria.
In 5 cases, the patient inherited 2 copies of the mutated gene from the same parent. Of the dominant mutations, 208 were de novo mutations not inherited from either parent, 32 were inherited, and 40 were not determined because parental samples were not available.
Among the de novo mutations, 5 demonstrated mosaicism, which suggested the mutation occurred after fertilization.
The researchers found 708 presumptive causative variant alleles in the 504 cases. Almost 30% of the diagnoses occurred in disease genes only identified by researchers in the last 3 years. In 65 cases, there was no available genetic test other than whole-exome sequencing to find the mutated gene at the time the test was ordered.
Twenty-three patients (about 5%) had mutations in 2 different genes, which could account for various aspects of the patient’s medical condition.
“Doctors generally try to find one diagnosis that explains all the issues a patient may have,” said study author Christine Eng, MD, of the Baylor College of Medicine.
“We have found that, in some cases, a patient may have a blended phenotype of 2 different conditions. That patients may have 2 different rare genetic diseases to explain their condition was an unexpected finding prior to the use of whole-exome sequencing.”
In the 2000 cases, incidental findings of medically actionable results that could result in early diagnosis, screening, or treatment were found in 92 patients. Three patients had more than 1 finding.
“Clinical exome sequencing can assist diagnosis in a wide range of disorders that are diagnostic dilemmas,” Dr Lupski said. “Rare variants and Mendelian disease are important contributors to disease populations. This is in sharp contrast to the thinking of population geneticists, who investigate how common variants contribute to disease susceptibility.”
“We find ‘rare variants’ in aggregate actually contribute to disease susceptibility in a big way. The individual diseases may be rare, but there are thousands of such diseases and many more being defined through genomics.”
Credit: Graham Colm
In a large study, whole-exome sequencing provided 25% of patients with a diagnosis related to a known genetic disease, giving young
patients and their parents some long-sought answers.
The technology was able to detect a number of rare genetic events and new mutations contributing to disease.
Among the medically actionable findings were mutations related to Fanconi anemia, erythrocytosis, hemolytic anemia, and von Willebrand disease.
“The findings in this report, I believe, will forever change the future practice of pediatrics and medicine as a whole,” said study author James R. Lupski, MD, PhD, of the Baylor College of Medicine in Houston.
“It is just a matter of time before genomics moves up on the physician’s list of things to do and is ordered before formulating a differential diagnosis. It will be the new ‘family history’ that, better yet, gets you both the important variants inherited from each parent and the new mutations that contribute to disease susceptibility.”
This research was published in JAMA and is set to be presented on October 21 at the American Society of Human Genetics Annual Meeting in San Diego.
The researchers had previously conducted a pilot study of whole-exome sequencing that included 250 patients and revealed a 25% molecular diagnostic rate.
This current study included 2000 patients (88% pediatric) with clinical whole-exome sequencing analyzed between June 2012 and August 2014. The majority of patients—87.8%—had neurological disorders or a developmental delay, and 12.2% had non-neurological disorders.
The researchers collected peripheral blood, tissue, or extracted DNA samples from patients and their parents. The team sequenced patients’ DNA and compared those results to the normal reference. Any disease-associated mutations were then compared with the parent’s DNA to determine if the child inherited it from one or both parents.
In all, 504 patients (25.2%) received a molecular diagnosis, and 58% of the diagnostic mutations had not previously been reported. Two hundred and eighty patients had a single mutation that caused disease, 181 were autosomal recessive, 65 were X-linked, and 1 was presumed inherited through the mitochondria.
In 5 cases, the patient inherited 2 copies of the mutated gene from the same parent. Of the dominant mutations, 208 were de novo mutations not inherited from either parent, 32 were inherited, and 40 were not determined because parental samples were not available.
Among the de novo mutations, 5 demonstrated mosaicism, which suggested the mutation occurred after fertilization.
The researchers found 708 presumptive causative variant alleles in the 504 cases. Almost 30% of the diagnoses occurred in disease genes only identified by researchers in the last 3 years. In 65 cases, there was no available genetic test other than whole-exome sequencing to find the mutated gene at the time the test was ordered.
Twenty-three patients (about 5%) had mutations in 2 different genes, which could account for various aspects of the patient’s medical condition.
“Doctors generally try to find one diagnosis that explains all the issues a patient may have,” said study author Christine Eng, MD, of the Baylor College of Medicine.
“We have found that, in some cases, a patient may have a blended phenotype of 2 different conditions. That patients may have 2 different rare genetic diseases to explain their condition was an unexpected finding prior to the use of whole-exome sequencing.”
In the 2000 cases, incidental findings of medically actionable results that could result in early diagnosis, screening, or treatment were found in 92 patients. Three patients had more than 1 finding.
“Clinical exome sequencing can assist diagnosis in a wide range of disorders that are diagnostic dilemmas,” Dr Lupski said. “Rare variants and Mendelian disease are important contributors to disease populations. This is in sharp contrast to the thinking of population geneticists, who investigate how common variants contribute to disease susceptibility.”
“We find ‘rare variants’ in aggregate actually contribute to disease susceptibility in a big way. The individual diseases may be rare, but there are thousands of such diseases and many more being defined through genomics.”
Ibrutinib gets EU approval for CLL, MCL
Credit: Steven Harbour
The European Commission has granted marketing approval for the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) in the European Union (EU).
The drug is now approved to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL), adults with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, and first-line CLL patients who have 17p deletion or TP53 mutation and are unsuitable for chemotherapy.
In the EU and all other countries except the US, ibrutinib is marketed by Janssen Pharmaceutical Companies. In the US, the drug is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
The EU approval of ibrutinib was based on data from a phase 2 study (PCYC-1104) in patients with MCL, the phase 3 RESONATE trial (PCYC-1112-CA) in CLL and small lymphocytic lymphoma (SLL), and a phase 1b/2 study (PCYC-1102) in CLL/SLL.
PCYC-1104: Ibrutinib in MCL
Results of this trial were presented at ASH 2012 and published in NEJM in 2013. The NEJM data included 111 patients who received ibrutinib at 560 mg daily in continuous, 28-day cycles until disease progression.
The overall response rate was 68%, with a complete response rate of 21% and a partial response rate of 47%. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months.
The estimated progression-free survival was 13.9 months, and the overall survival was not reached. The estimated rate of overall survival was 58% at 18 months.
Common nonhematologic adverse events included diarrhea (50%), fatigue (41%), nausea (31%), peripheral edema (28%), dyspnea (27%), constipation (25%), upper respiratory tract infection (23%), vomiting (23%), and decreased appetite (21%). The most common grade 3, 4, or 5 infection was pneumonia (6%).
Grade 3 and 4 hematologic adverse events included neutropenia (16%), thrombocytopenia (11%), and anemia (10%). Grade 3 bleeding events occurred in 5 patients.
RESONATE: Ibrutinib in CLL/SLL
Results of the RESONATE trial were reported at EHA 2014 and published in NEJM in July. This trial was stopped early after an interim analysis showed that ibrutinib-treated patients experienced a 78% reduction in the risk of disease progression or death.
The trial included 391 patients with relapsed or refractory CLL or SLL who were randomized to receive ibrutinib (n=195) or ofatumumab (n=196). Patients in the ofatumumab arm were allowed to cross over to ibrutinib if they progressed (n=57). The median time on study was 9.4 months.
The best overall response rate was higher in the ibrutinib arm than the ofatumumab arm, at 78% and 11%, respectively. And ibrutinib significantly prolonged progression-free survival. The median was 8.1 months in the ofatumumab arm and was not reached in the ibrutinib arm (P<0.0001).
Ibrutinib significantly prolonged overall survival as well. The median overall survival was not reached in either arm, but the hazard ratio was 0.434 (P=0.0049).
Adverse events occurred in 99% of patients in the ibrutinib arm and 98% of those in the ofatumumab arm. Grade 3/4 events occurred in 51% and 39% of patients, respectively.
Atrial fibrillation, bleeding-related events, diarrhea, and arthralgia were more common in the ibrutinib arm. Infusion-related reactions, peripheral sensory neuropathy, urticaria, night sweats, and pruritus were more common in the ofatumumab arm.
PCYC-1102: Ibrutinib in CLL/SLL
Results of this phase 1b/2 trial were published in The Lancet Oncology in January. The trial enrolled 29 patients with previously untreated CLL and 2 with SLL.
They received 28-day cycles of once-daily ibrutinib at 420 mg or 840 mg. The 840 mg dose was discontinued after enrollment had begun because the doses showed comparable activity.
After a median follow-up of 22.1 months, 71% of patients achieved an objective response. Four patients (13%) had a complete response. The median time to response was 1.9 months.
Study investigators did not establish whether ibrutinib confers improvements in survival or disease-related symptoms.
Common adverse events included diarrhea (68%), nausea (48%), fatigue (32%), peripheral edema (29%), hypertension (29%), dizziness (26%), dyspepsia (26%), upper respiratory tract infection (26%), arthralgia (23%), constipation (23%), urinary tract infection (23%), and vomiting (23%).
Grade 3 adverse events included diarrhea (13%), fatigue (3%), hypertension (6%), dizziness (3%), urinary tract infection (3%), headache (3%), back pain (3%), and neutropenia (3%). One patient (3%) had grade 4 thrombocytopenia.
Credit: Steven Harbour
The European Commission has granted marketing approval for the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) in the European Union (EU).
The drug is now approved to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL), adults with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, and first-line CLL patients who have 17p deletion or TP53 mutation and are unsuitable for chemotherapy.
In the EU and all other countries except the US, ibrutinib is marketed by Janssen Pharmaceutical Companies. In the US, the drug is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
The EU approval of ibrutinib was based on data from a phase 2 study (PCYC-1104) in patients with MCL, the phase 3 RESONATE trial (PCYC-1112-CA) in CLL and small lymphocytic lymphoma (SLL), and a phase 1b/2 study (PCYC-1102) in CLL/SLL.
PCYC-1104: Ibrutinib in MCL
Results of this trial were presented at ASH 2012 and published in NEJM in 2013. The NEJM data included 111 patients who received ibrutinib at 560 mg daily in continuous, 28-day cycles until disease progression.
The overall response rate was 68%, with a complete response rate of 21% and a partial response rate of 47%. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months.
The estimated progression-free survival was 13.9 months, and the overall survival was not reached. The estimated rate of overall survival was 58% at 18 months.
Common nonhematologic adverse events included diarrhea (50%), fatigue (41%), nausea (31%), peripheral edema (28%), dyspnea (27%), constipation (25%), upper respiratory tract infection (23%), vomiting (23%), and decreased appetite (21%). The most common grade 3, 4, or 5 infection was pneumonia (6%).
Grade 3 and 4 hematologic adverse events included neutropenia (16%), thrombocytopenia (11%), and anemia (10%). Grade 3 bleeding events occurred in 5 patients.
RESONATE: Ibrutinib in CLL/SLL
Results of the RESONATE trial were reported at EHA 2014 and published in NEJM in July. This trial was stopped early after an interim analysis showed that ibrutinib-treated patients experienced a 78% reduction in the risk of disease progression or death.
The trial included 391 patients with relapsed or refractory CLL or SLL who were randomized to receive ibrutinib (n=195) or ofatumumab (n=196). Patients in the ofatumumab arm were allowed to cross over to ibrutinib if they progressed (n=57). The median time on study was 9.4 months.
The best overall response rate was higher in the ibrutinib arm than the ofatumumab arm, at 78% and 11%, respectively. And ibrutinib significantly prolonged progression-free survival. The median was 8.1 months in the ofatumumab arm and was not reached in the ibrutinib arm (P<0.0001).
Ibrutinib significantly prolonged overall survival as well. The median overall survival was not reached in either arm, but the hazard ratio was 0.434 (P=0.0049).
Adverse events occurred in 99% of patients in the ibrutinib arm and 98% of those in the ofatumumab arm. Grade 3/4 events occurred in 51% and 39% of patients, respectively.
Atrial fibrillation, bleeding-related events, diarrhea, and arthralgia were more common in the ibrutinib arm. Infusion-related reactions, peripheral sensory neuropathy, urticaria, night sweats, and pruritus were more common in the ofatumumab arm.
PCYC-1102: Ibrutinib in CLL/SLL
Results of this phase 1b/2 trial were published in The Lancet Oncology in January. The trial enrolled 29 patients with previously untreated CLL and 2 with SLL.
They received 28-day cycles of once-daily ibrutinib at 420 mg or 840 mg. The 840 mg dose was discontinued after enrollment had begun because the doses showed comparable activity.
After a median follow-up of 22.1 months, 71% of patients achieved an objective response. Four patients (13%) had a complete response. The median time to response was 1.9 months.
Study investigators did not establish whether ibrutinib confers improvements in survival or disease-related symptoms.
Common adverse events included diarrhea (68%), nausea (48%), fatigue (32%), peripheral edema (29%), hypertension (29%), dizziness (26%), dyspepsia (26%), upper respiratory tract infection (26%), arthralgia (23%), constipation (23%), urinary tract infection (23%), and vomiting (23%).
Grade 3 adverse events included diarrhea (13%), fatigue (3%), hypertension (6%), dizziness (3%), urinary tract infection (3%), headache (3%), back pain (3%), and neutropenia (3%). One patient (3%) had grade 4 thrombocytopenia.
Credit: Steven Harbour
The European Commission has granted marketing approval for the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) in the European Union (EU).
The drug is now approved to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL), adults with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, and first-line CLL patients who have 17p deletion or TP53 mutation and are unsuitable for chemotherapy.
In the EU and all other countries except the US, ibrutinib is marketed by Janssen Pharmaceutical Companies. In the US, the drug is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
The EU approval of ibrutinib was based on data from a phase 2 study (PCYC-1104) in patients with MCL, the phase 3 RESONATE trial (PCYC-1112-CA) in CLL and small lymphocytic lymphoma (SLL), and a phase 1b/2 study (PCYC-1102) in CLL/SLL.
PCYC-1104: Ibrutinib in MCL
Results of this trial were presented at ASH 2012 and published in NEJM in 2013. The NEJM data included 111 patients who received ibrutinib at 560 mg daily in continuous, 28-day cycles until disease progression.
The overall response rate was 68%, with a complete response rate of 21% and a partial response rate of 47%. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months.
The estimated progression-free survival was 13.9 months, and the overall survival was not reached. The estimated rate of overall survival was 58% at 18 months.
Common nonhematologic adverse events included diarrhea (50%), fatigue (41%), nausea (31%), peripheral edema (28%), dyspnea (27%), constipation (25%), upper respiratory tract infection (23%), vomiting (23%), and decreased appetite (21%). The most common grade 3, 4, or 5 infection was pneumonia (6%).
Grade 3 and 4 hematologic adverse events included neutropenia (16%), thrombocytopenia (11%), and anemia (10%). Grade 3 bleeding events occurred in 5 patients.
RESONATE: Ibrutinib in CLL/SLL
Results of the RESONATE trial were reported at EHA 2014 and published in NEJM in July. This trial was stopped early after an interim analysis showed that ibrutinib-treated patients experienced a 78% reduction in the risk of disease progression or death.
The trial included 391 patients with relapsed or refractory CLL or SLL who were randomized to receive ibrutinib (n=195) or ofatumumab (n=196). Patients in the ofatumumab arm were allowed to cross over to ibrutinib if they progressed (n=57). The median time on study was 9.4 months.
The best overall response rate was higher in the ibrutinib arm than the ofatumumab arm, at 78% and 11%, respectively. And ibrutinib significantly prolonged progression-free survival. The median was 8.1 months in the ofatumumab arm and was not reached in the ibrutinib arm (P<0.0001).
Ibrutinib significantly prolonged overall survival as well. The median overall survival was not reached in either arm, but the hazard ratio was 0.434 (P=0.0049).
Adverse events occurred in 99% of patients in the ibrutinib arm and 98% of those in the ofatumumab arm. Grade 3/4 events occurred in 51% and 39% of patients, respectively.
Atrial fibrillation, bleeding-related events, diarrhea, and arthralgia were more common in the ibrutinib arm. Infusion-related reactions, peripheral sensory neuropathy, urticaria, night sweats, and pruritus were more common in the ofatumumab arm.
PCYC-1102: Ibrutinib in CLL/SLL
Results of this phase 1b/2 trial were published in The Lancet Oncology in January. The trial enrolled 29 patients with previously untreated CLL and 2 with SLL.
They received 28-day cycles of once-daily ibrutinib at 420 mg or 840 mg. The 840 mg dose was discontinued after enrollment had begun because the doses showed comparable activity.
After a median follow-up of 22.1 months, 71% of patients achieved an objective response. Four patients (13%) had a complete response. The median time to response was 1.9 months.
Study investigators did not establish whether ibrutinib confers improvements in survival or disease-related symptoms.
Common adverse events included diarrhea (68%), nausea (48%), fatigue (32%), peripheral edema (29%), hypertension (29%), dizziness (26%), dyspepsia (26%), upper respiratory tract infection (26%), arthralgia (23%), constipation (23%), urinary tract infection (23%), and vomiting (23%).
Grade 3 adverse events included diarrhea (13%), fatigue (3%), hypertension (6%), dizziness (3%), urinary tract infection (3%), headache (3%), back pain (3%), and neutropenia (3%). One patient (3%) had grade 4 thrombocytopenia.
Bigger Than His Bite
A 58‐year‐old male presented to a local community hospital emergency department with fever and altered mental status. Earlier in the day he had complained of chills, swollen tongue, numbness and tingling in his extremities with associated burning pain, and generalized weakness. En route to the emergency department, he was extremely agitated and moving uncontrollably. On arrival, he was noted to be in respiratory distress and was intubated for hypoxic respiratory failure. He was subsequently transferred to an academic medical center, and in transit was noted to have sustained supraventricular tachycardia with a heart rate of 160 beats per minute.
Although the differential for altered mental status is broad, associated fever limits the main diagnostic considerations to infectious, toxic, and some inflammatory disorders. Confusion and fever are most concerning for a central nervous system infection, either meningitis or encephalitis. Sepsis from a broader range of infectious etiologies may also present with these symptoms. His respiratory failure could represent acute respiratory distress syndrome (ARDS) due to sepsis, aspiration, or a manifestation of a multisystem inflammatory disease.
He did not have any significant past medical or surgical history. Three days before his initial presentation, the patient was bitten on the left hand and forearm while breaking up a dogfight. The dogs that bit him belonged to his son, but were unvaccinated. He did not seek medical attention and it was unclear how he treated his wounds at home.
Dogs may serve as vectors for a number of zoonoses. Species of both Pasteurella and Capnocytophaga may cause sepsis and rarely meningitis as a consequence of dog bites. The incubation period of 3 days, though brief, does not exclude either infection. Rabies encephalitis is also possible, particularly given the dogs' unvaccinated status. However, the typical incubation period for rabies is on the order of months, and a 3‐day interval from inoculation to symptoms would be highly unusual. Although other explanations for his symptoms are more likely, he should still be considered for vaccination and rabies immune globulin. The dogs should be observed for clinical manifestations of rabies. Despite the patient's history of dog bite, a broad differential diagnosis must be maintained.
The patient lived in Michigan and worked in a chemical factory driving equipment without any hazardous exposures. He did not have any allergies. He drank 6 beers per day; he did not smoke cigarettes and had no history of illicit drug use. He was single and had 4 adult children.
His history of heavy alcohol consumption raises several additional possibilities. Delirium tremens, alcohol withdrawal seizures, or hepatic encephalopathy as a consequence of alcoholic cirrhosis are both potential contributors to his presentation. Furthermore, the physiologic signs of alcohol withdrawal are similar to many critical illnesses, which may present a diagnostic challenge. The patient's history of employment at a chemical factory is intriguing, though the details of any potential occupational exposures are unknown. Carbon monoxide poisoning can present with altered mental status and agitation, whereas anticholinergic toxicity can present with fever, tachycardia, and altered mental status; however, there is no obvious source of exposure to either.
On physical examination, the patient was intubated with a Glasgow Coma Scale of 11 without sedation; serial examinations revealed a fluctuating level of consciousness. His temperature was 38.1C, heart rate was 158 beats per minute, and blood pressure was 93/68 mm Hg. Mechanical ventilation was provided with assist control mode, a respiratory rate of 28 breaths per minute, tidal volume 466 mL, and positive end expiratory pressure of 20 cm of water. His oxygen saturation was 81% on 100% oxygen. Examination of his neck exhibited a large left neck hematoma from the unsuccessful placement of an external jugular intravenous catheter. Pupils were 4 mm in diameter and minimally reactive. There was no scleral icterus. Cardiac exam revealed tachycardia and regular rhythm without murmurs, rubs, or gallops. Lung exam was significant for bilateral rhonchi and minimal tracheal secretions. Extremity exam revealed 0.25 to 1.5 cm in diameter puncture bite marks with abrasions on his left third and fourth upper extremity digits as well as on his left forearm. Skin exam was diffusely cool with a mottled appearance. Neurologic exam revealed absent deep tendon reflexes throughout and apparent flaccid paralysis of all 4 extremities. Examination of the abdomen, lymph nodes, mouth, and throat were unremarkable.
The shock associated with sepsis is typically distributive, with intense vasodilation that classically leads to warm extremities. His mottled, cool extremities raise concern for disseminated intravascular coagulation (DIC), which can be seen in patients with septic shock, particularly cases caused by meningococcal disease and Capnocytophaga infections. His neurologic examination is typical of lower motor neuron disease, although acute upper motor neuron lesions can also be associated with hyporeflexia. Rabies can manifest as flaccid paralysis, but this would classically predate the mental status changes. Rabies remains a consideration, albeit a less likely one. Zoonoses, particularly Capnocytophaga and Pasteurella, are possible; however, a thorough search for other infections leading to sepsis is still indicated. His lung findings suggest severe ARDS.
The white blood cell count was 5,900/mm3, with 91% neutrophils, 6.6% lymphocytes, and 0.5% monocytes. The hemoglobin level was 13.0 g/dL, and the platelet count was 12,000/mm3. The fibrinogen level was 89 mg/dL (normal range 200400 mg/dL), international normalized ratio and partial‐thromboplastin time were 4.6 (normal range 0.8 to 1.1) and greater than 120.0 seconds (normal range 2535 seconds), respectively. Lactate dehydrogenase level was 698 IU/L (normal 120240 IU/L), and haptoglobin was 54 mg/dL (normal 41165 mg/dL). Serum sodium was 136 mmol/L, potassium 4.6 mmol/L, chloride 101 mmol/L, bicarbonate 16 mmol/L, blood urea nitrogen 29 mg/dL, creatinine 2.28 mg/dL, glucose 123 mg/dL, calcium 7.0 mg/dL, magnesium 1.7 mg/dL, and phosphorus 7.2 mg/dL. Total protein was 4.3 g/dL (normal 6.08.3 g/dL), albumin 2.5 g/dL (normal 3.54.9 g/dL), total bilirubin 2.3 mg/dL (normal 0.21.2 mg/dL), aspartate aminotransferase 71 IU/L (normal 830 IU/L), alanine aminotransferase 29 IU/L (normal 735 IU/L), and alkaline phosphatase 107 IU/L (normal 30130 IU/L). The serum troponin‐I level was 0.76 ng/mL, creatine phosphokinase 397 ng/mL, and creatine kinase‐myocardial band 3.5 ng/mL. Initial arterial blood gas analysis revealed a pH of 7.00, pCO2 57 mm Hg, pO2 98 mm Hg, and a lactic acid of 6.5 mmol/L (normal 0.52.2 mmol/L).
The patient has a normal absolute white blood cell count in the setting of septic shock. He has a relative neutrophilia and a marked leukopenia, both of which can be seen in overwhelming infections. The patient's arterial blood gas analysis indicates he has a mixed metabolic and respiratory acidosis. The normal physiologic response to metabolic acidosis is to increase minute ventilation and induce a compensatory respiratory alkalosis. His concomitant respiratory acidosis in the face of mechanical ventilation and presumed adequate minute ventilation suggests severely impaired alveolar gas exchange, most likely from ARDS. He has numerous other metabolic abnormalities, including acute kidney injury, DIC, and hemolytic anemia, all of which may be seen with severe bacterial infections or septic shock. Neisseria meningitidis and other gram‐negative infections would be of particular concern in this case. The combination of fever, altered mental status, thrombocytopenia, hemolytic anemia, and renal failure could be consistent with thrombotic thrombocytopenic purpura. However, the prolonged coagulation studies are much more consistent with DIC.
Intravenous antimicrobials were administered including ceftriaxone (initiated in the emergency department of the transferring hospital), ampicillin, vancomycin, piperacillin/tazobactam, clindamycin, metronidazole, doxycycline, and acyclovir. He received tetanus and rabies vaccines as well as tetanus and rabies immune globulin. The patient was given aggressive intravenous crystalloid fluids with minimal response in blood pressure. Intravenous norepinephrine was initiated to maintain a mean arterial pressure above 65 mm Hg. A plain chest radiograph (Figure 1) revealed perihilar airspace opacities. Head computed tomography without contrast revealed global cerebral volume loss greater than expected for the patient's age; no evidence of intracranial hemorrhage, mass effect, or edema; and proptosis of the eyes with adjacent preseptal soft tissue swelling without evidence of retrobulbar hemorrhage or vascular engorgement. Ultrasound of the left neck hematoma was negative for pulsatile mass. Electrocardiogram (ECG) revealed sinus tachycardia without evidence of ischemic changes. A bedside transthoracic echocardiogram showed hyperdynamic changes without evidence of hypokinesis but with inspiratory collapse of the inferior vena cava. Abdominal ultrasound was normal. Plain radiographs of the left hand (Figure 2) identified only mild soft tissue swelling over the dorsum of the hand. An ultrasound of the left hand and left forearm did not identify any abnormal fluid collection. A dialysis catheter was placed after the patient received platelets and fresh frozen plasma for initiation of continuous renal replacement therapy.
Given this patient's fulminant presentation, he was appropriately started on a very broad anti‐infective regimen. Although fungal infections are less likely, his current antimicrobial regimen lacks antifungal coverage. His finding of proptosis raises concern for mucormycosis, although the time course and clinical presentation are somewhat atypical. Because of the severity of his presentation, initiation of amphotericin B could be considered if he fails to quickly respond to the current regimen. There is no known effective treatment for rabies. Thus, if his presentation is due to rabies encephalitis, rabies vaccine and immunoglobulin will not be effective at treating active rabies infection. However, given his exposure history and the dogs' unvaccinated status, postexposure prophylaxis was appropriate to prevent future development of rabies. The inspiratory collapse and hyperdynamic ventricular response seen on his bedside echocardiogram is consistent with decreased effective circulating volume from sepsis or severe hypovolemia rather than acute heart failure.
Less than 36 hours after admission (60 hours after his symptoms began), the patient's oxygenation status had not improved. He developed diffuse cutaneous purpura with hemorrhagic bullae. Liver, renal, and cardiac function markers were all markedly abnormal. All cultures from the transferring hospital, collected before antibiotics were initiated, were negative to date. However, Gram stain of blood cultures performed at the academic medical center revealed possible gram‐negative rods. The patient remained unresponsive without sedation. ECG revealed evidence of inferior and anterolateral ischemia. The patient's family was informed of his persistently deteriorating condition and elected to pursue comfort measures. Two hours later the patient expired. The family agreed to an autopsy.
This patient succumbed to overwhelming sepsis and multiorgan failure. Although the etiologic pathogen is not immediately clear, several clues point to a likely unifying diagnosis. First, he has a history of a recent dog bite with minimal local evidence of infection. Second, he presented with fulminant sepsis with DIC, hemolytic anemia, and diffuse mottling that progressed to purpura fulminans. Third, a possible gram‐negative rod was isolated on blood Gram stain. Fourth, he has a history of heavy alcohol use. For these reasons, Capnocytophaga canimorsus is the most likely underlying etiology. C canimorsus is a fastidious gram‐negative coccobacillus that is an uncommon cause of fulminant sepsis in patients with dog bites. It is difficult to isolate due to culture growth requirements, which may explain the negative blood cultures in this case. Patients with alcoholism are predisposed to fulminant sepsis from C canimorsus, which often presents with hepatic and renal failure. The myocardial ischemia may be secondary to the metabolic and thrombotic complications of sepsis.
On autopsy, there was purpura fulminans involving over 90% of the total body surface area as well as skin slippage and loose bullae of greater than 75% of the total body surface area. There was infarction of the kidneys, liver, spleen, and adrenal glands as well as focal contraction bands of necrosis of the myocardium. The lungs showed diffuse alveolar damage. There was hemorrhage, edema, and necrosis seen in sections taken from the puncture wounds. Following the patient's death, it was reported by the transferring institution that C canimorsus was identified from 2 of 2 antemortem blood cultures, and pan‐sensitive Acinetobacter lwoffii in 1 of 2 blood cultures, though no sensitivities were performed on the C canimorsus isolate. In addition, antemortem cultures obtained at the academic medical center identified Capnocytophaga species in 1 of 2 peripheral blood culture specimens; sensitivities were not performed. Autopsy determined the cause of death in this patient to be septic complications of dog bite.
COMMENTARY
Dog bites are frequent, with over 12,000 occurring daily in the United States; of these, approximately 20% require medical attention.[1] Although most patients rapidly recover with conservative management, even initially benign‐appearing injuries can lead to long‐term morbidity or death. The hands are most often affected and are associated with more frequent need for both antibiotics and surgical intervention.[2, 3] The severity of injury does not correlate with subsequent infections.[3]
Management of dog bite injuries includes careful wound management. All patients with moderate to severe injury should be assessed within 48 hours by physical examination and radiography to assess the degree of injury and any associated nerve, tendon, joint, or bone damage. If there is concern for rabies based on history or vaccination status of the animal, prompt irrigation and debridement is crucial. Antimicrobial prophylaxis, typically with amoxicillinclavulanate, should be given to high‐risk patients, such as those with cirrhosis, asplenia, or other immunosuppressing conditions.[4] Most infections are caused by Pasteurella and Bacteroides, whereas Capnocytophaga may cause severe disease, particularly in patients with immunosuppression or excessive alcohol intake.[5] This patient was at increased risk of infection due to his late presentation following the initial bite and consequent delayed wound care, injury to the hand, and his history of alcoholism.[4]
Several members of the genus Capnocytophaga have been found in the oral cavities of both humans and canines. C canimorsus, found only in canine or feline oral cavities, is the only member of the genus known to cause human disease.[6] It is a fastidious gram‐negative rod requiring an environment enriched with carbon dioxide, making it notoriously difficult to isolate. Cultures typically do not show growth for 5 to 7 days; thus, it is not surprising all cultures were initially negative in this case.[4, 7] C canimorsus is a well‐described cause of sepsis related to dog bites, with some cases bearing similarity to fulminant meningococcal disease.[8] Severe illness typically occurs in immunosuppressed patients, particularly those with asplenia or cirrhosis.[9, 10] The pathophysiology of fulminant C canimorsus infections is not well described. It has been suggested that certain strains may produce a toxin that inhibits macrophages and inactivates tumor necrosis factor in humans, although this is not yet widely accepted.[11] Treatment of C canimorsus involves early administration of effective antimicrobials, supportive care, and standard management of the bite injury. C canimorsus is susceptible to several classes of antibiotics; ‐lactams, such as penicillin derivatives and cephalosporins, and potentiated sulphonamides, such as trimethoprim/sulfamethoxazole, typically have the best in vitro activity.[12] As illustrated in this case, even with prompt, effective antibiotic administration, C canimorsus infection can progress to DIC, multisystem organ failure, and death.[9]
A lwoffii was also identified, but was almost certainly a contaminant. It is a gram‐negative bacillus that is widely distributed throughout the environment. Commonly found on human skin and within the human oropharynx, it rarely causes human disease. Clinical manifestations of infection with A lwoffii are typically mild, and include superficial skin and soft tissue infection, urinary tract infection, and rarely bacteremia. Because of the severe presentation in this case and the compelling alternative explanation of C canimorsus, A lwoffii was almost certainly a contaminant.
Rabies was an intriguing possibility in this case given the unvaccinated status of the dogs and the patient's prominent neurologic findings. Clinicians must consider the possibility of rabies in any patient with a bite injury from an unvaccinated dog. However, rabies remains extremely rare in the developed world as a result of the overwhelming success of animal vaccination and postexposure prophylaxis. Furthermore, rabies typically has an incubation period of several months. If rabies had caused this patient's presentation, rabies immunoglobulin would have been ineffective. Nevertheless, rabies prophylaxis with rabies immunoglobulin and vaccination is appropriate to prevent subsequent disease unless rabies infection can be definitively excluded.[13]
This patient presented with septic shock, DIC, and multisystem organ failure after a dog bite. The discussant quickly recognized the propensity of Capnocytophaga to cause this constellation of findings in alcoholic patients after dog bites. This patient did not have cirrhosis or asplenia, both of which are known risk factors for C canimorsus infection; however, the fulminant presentation made C canimorsus a necessary consideration. Ultimately, the dramatic nature of the patient's presentation combined with his history of heavy alcohol intake led the discussant to the correct diagnosis of septic shock secondary to C canimorsus infection complicating a benign‐appearing dog bite. Clinicians caring for patients who present with sepsis after a recent dog bite should consider C canimorsus, remembering that on occasion, a dog's bark may not be bigger than his bite.
TEACHING POINTS
- The initial management of moderate or severe dog‐bite injuries includes careful wound assessment and radiography to exclude any associated bone, nerve, joint, or tendon injury.
- Immunosuppressed patients with dog bites, including those with cirrhosis or asplenia, should receive amoxicillin/clavulanate prophylaxis.
- C canimorsus is a fastidious gram‐negative bacillus that may cause fulminant sepsis after dog bites. It is associated with DIC, purpura fulminans, and multisystem organ failure.
- ‐lactam antibiotics, such as penicillin derivatives or cephalosporins, or sulphonamides, are the treatment of choice for C canimorsus.
Disclosure
Nothing to report.
- , , , . Dog bites: still a problem? Injury Prev. 2008;14(5):296–301.
- , , , . Dog bite injuries: primary and secondary emergency department presentations—a retrospective cohort study. ScientificWorldJournal. 2013;2013:393176.
- , , , et al. Management of vascular trauma from dog bites. J Vascular Surg. 2013;58(5):1346–1352.
- , . Dog bites. BMJ. 2007;334(7590):413–417.
- , , , . Bacterial infections as complications of dog bites [in Danish]. Ugeskrift Laeger. 1998;160(34):4860–4863.
- , , , , . Bite‐related and septic syndromes caused by cats and dogs. Lancet Infect Dis. 2009;9(7):439–447.
- , , , , . Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med. 1999;340(2):85–92.
- , , , . Diagnosing Capnocytophaga canimorsus infections. Emerg Infect Dis. 2006;12(2):340–342.
- , , . Capnocytophaga canimorsus septicemia in Denmark, 1982–1995: review of 39 cases. Clinical Infect Dis. 1996;23(1):71–75.
- . Consequences of alcohol consumption on host defence. Alcohol Alcohol. 1999;34(6):830–841.
- , , , , , . Molecular characterization of Capnocytophaga canimorsus and other canine Capnocytophaga spp. and assessment by PCR of their frequencies in dogs. J Clin Microbiol. 2009;47(10):3218–3225.
- , , , . The bacteriology and antimicrobial susceptibility of infected and non‐infected dog bite wounds: fifty cases. Vet Microbiol. 2008;127(3‐4):360–368.
- U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Human rabies—Alabama, Tennessee, and Texas, 1994. Morbidity and Mortality Weekly Report; 1995. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00036736.htm. Accessed March 1, 2014.
A 58‐year‐old male presented to a local community hospital emergency department with fever and altered mental status. Earlier in the day he had complained of chills, swollen tongue, numbness and tingling in his extremities with associated burning pain, and generalized weakness. En route to the emergency department, he was extremely agitated and moving uncontrollably. On arrival, he was noted to be in respiratory distress and was intubated for hypoxic respiratory failure. He was subsequently transferred to an academic medical center, and in transit was noted to have sustained supraventricular tachycardia with a heart rate of 160 beats per minute.
Although the differential for altered mental status is broad, associated fever limits the main diagnostic considerations to infectious, toxic, and some inflammatory disorders. Confusion and fever are most concerning for a central nervous system infection, either meningitis or encephalitis. Sepsis from a broader range of infectious etiologies may also present with these symptoms. His respiratory failure could represent acute respiratory distress syndrome (ARDS) due to sepsis, aspiration, or a manifestation of a multisystem inflammatory disease.
He did not have any significant past medical or surgical history. Three days before his initial presentation, the patient was bitten on the left hand and forearm while breaking up a dogfight. The dogs that bit him belonged to his son, but were unvaccinated. He did not seek medical attention and it was unclear how he treated his wounds at home.
Dogs may serve as vectors for a number of zoonoses. Species of both Pasteurella and Capnocytophaga may cause sepsis and rarely meningitis as a consequence of dog bites. The incubation period of 3 days, though brief, does not exclude either infection. Rabies encephalitis is also possible, particularly given the dogs' unvaccinated status. However, the typical incubation period for rabies is on the order of months, and a 3‐day interval from inoculation to symptoms would be highly unusual. Although other explanations for his symptoms are more likely, he should still be considered for vaccination and rabies immune globulin. The dogs should be observed for clinical manifestations of rabies. Despite the patient's history of dog bite, a broad differential diagnosis must be maintained.
The patient lived in Michigan and worked in a chemical factory driving equipment without any hazardous exposures. He did not have any allergies. He drank 6 beers per day; he did not smoke cigarettes and had no history of illicit drug use. He was single and had 4 adult children.
His history of heavy alcohol consumption raises several additional possibilities. Delirium tremens, alcohol withdrawal seizures, or hepatic encephalopathy as a consequence of alcoholic cirrhosis are both potential contributors to his presentation. Furthermore, the physiologic signs of alcohol withdrawal are similar to many critical illnesses, which may present a diagnostic challenge. The patient's history of employment at a chemical factory is intriguing, though the details of any potential occupational exposures are unknown. Carbon monoxide poisoning can present with altered mental status and agitation, whereas anticholinergic toxicity can present with fever, tachycardia, and altered mental status; however, there is no obvious source of exposure to either.
On physical examination, the patient was intubated with a Glasgow Coma Scale of 11 without sedation; serial examinations revealed a fluctuating level of consciousness. His temperature was 38.1C, heart rate was 158 beats per minute, and blood pressure was 93/68 mm Hg. Mechanical ventilation was provided with assist control mode, a respiratory rate of 28 breaths per minute, tidal volume 466 mL, and positive end expiratory pressure of 20 cm of water. His oxygen saturation was 81% on 100% oxygen. Examination of his neck exhibited a large left neck hematoma from the unsuccessful placement of an external jugular intravenous catheter. Pupils were 4 mm in diameter and minimally reactive. There was no scleral icterus. Cardiac exam revealed tachycardia and regular rhythm without murmurs, rubs, or gallops. Lung exam was significant for bilateral rhonchi and minimal tracheal secretions. Extremity exam revealed 0.25 to 1.5 cm in diameter puncture bite marks with abrasions on his left third and fourth upper extremity digits as well as on his left forearm. Skin exam was diffusely cool with a mottled appearance. Neurologic exam revealed absent deep tendon reflexes throughout and apparent flaccid paralysis of all 4 extremities. Examination of the abdomen, lymph nodes, mouth, and throat were unremarkable.
The shock associated with sepsis is typically distributive, with intense vasodilation that classically leads to warm extremities. His mottled, cool extremities raise concern for disseminated intravascular coagulation (DIC), which can be seen in patients with septic shock, particularly cases caused by meningococcal disease and Capnocytophaga infections. His neurologic examination is typical of lower motor neuron disease, although acute upper motor neuron lesions can also be associated with hyporeflexia. Rabies can manifest as flaccid paralysis, but this would classically predate the mental status changes. Rabies remains a consideration, albeit a less likely one. Zoonoses, particularly Capnocytophaga and Pasteurella, are possible; however, a thorough search for other infections leading to sepsis is still indicated. His lung findings suggest severe ARDS.
The white blood cell count was 5,900/mm3, with 91% neutrophils, 6.6% lymphocytes, and 0.5% monocytes. The hemoglobin level was 13.0 g/dL, and the platelet count was 12,000/mm3. The fibrinogen level was 89 mg/dL (normal range 200400 mg/dL), international normalized ratio and partial‐thromboplastin time were 4.6 (normal range 0.8 to 1.1) and greater than 120.0 seconds (normal range 2535 seconds), respectively. Lactate dehydrogenase level was 698 IU/L (normal 120240 IU/L), and haptoglobin was 54 mg/dL (normal 41165 mg/dL). Serum sodium was 136 mmol/L, potassium 4.6 mmol/L, chloride 101 mmol/L, bicarbonate 16 mmol/L, blood urea nitrogen 29 mg/dL, creatinine 2.28 mg/dL, glucose 123 mg/dL, calcium 7.0 mg/dL, magnesium 1.7 mg/dL, and phosphorus 7.2 mg/dL. Total protein was 4.3 g/dL (normal 6.08.3 g/dL), albumin 2.5 g/dL (normal 3.54.9 g/dL), total bilirubin 2.3 mg/dL (normal 0.21.2 mg/dL), aspartate aminotransferase 71 IU/L (normal 830 IU/L), alanine aminotransferase 29 IU/L (normal 735 IU/L), and alkaline phosphatase 107 IU/L (normal 30130 IU/L). The serum troponin‐I level was 0.76 ng/mL, creatine phosphokinase 397 ng/mL, and creatine kinase‐myocardial band 3.5 ng/mL. Initial arterial blood gas analysis revealed a pH of 7.00, pCO2 57 mm Hg, pO2 98 mm Hg, and a lactic acid of 6.5 mmol/L (normal 0.52.2 mmol/L).
The patient has a normal absolute white blood cell count in the setting of septic shock. He has a relative neutrophilia and a marked leukopenia, both of which can be seen in overwhelming infections. The patient's arterial blood gas analysis indicates he has a mixed metabolic and respiratory acidosis. The normal physiologic response to metabolic acidosis is to increase minute ventilation and induce a compensatory respiratory alkalosis. His concomitant respiratory acidosis in the face of mechanical ventilation and presumed adequate minute ventilation suggests severely impaired alveolar gas exchange, most likely from ARDS. He has numerous other metabolic abnormalities, including acute kidney injury, DIC, and hemolytic anemia, all of which may be seen with severe bacterial infections or septic shock. Neisseria meningitidis and other gram‐negative infections would be of particular concern in this case. The combination of fever, altered mental status, thrombocytopenia, hemolytic anemia, and renal failure could be consistent with thrombotic thrombocytopenic purpura. However, the prolonged coagulation studies are much more consistent with DIC.
Intravenous antimicrobials were administered including ceftriaxone (initiated in the emergency department of the transferring hospital), ampicillin, vancomycin, piperacillin/tazobactam, clindamycin, metronidazole, doxycycline, and acyclovir. He received tetanus and rabies vaccines as well as tetanus and rabies immune globulin. The patient was given aggressive intravenous crystalloid fluids with minimal response in blood pressure. Intravenous norepinephrine was initiated to maintain a mean arterial pressure above 65 mm Hg. A plain chest radiograph (Figure 1) revealed perihilar airspace opacities. Head computed tomography without contrast revealed global cerebral volume loss greater than expected for the patient's age; no evidence of intracranial hemorrhage, mass effect, or edema; and proptosis of the eyes with adjacent preseptal soft tissue swelling without evidence of retrobulbar hemorrhage or vascular engorgement. Ultrasound of the left neck hematoma was negative for pulsatile mass. Electrocardiogram (ECG) revealed sinus tachycardia without evidence of ischemic changes. A bedside transthoracic echocardiogram showed hyperdynamic changes without evidence of hypokinesis but with inspiratory collapse of the inferior vena cava. Abdominal ultrasound was normal. Plain radiographs of the left hand (Figure 2) identified only mild soft tissue swelling over the dorsum of the hand. An ultrasound of the left hand and left forearm did not identify any abnormal fluid collection. A dialysis catheter was placed after the patient received platelets and fresh frozen plasma for initiation of continuous renal replacement therapy.
Given this patient's fulminant presentation, he was appropriately started on a very broad anti‐infective regimen. Although fungal infections are less likely, his current antimicrobial regimen lacks antifungal coverage. His finding of proptosis raises concern for mucormycosis, although the time course and clinical presentation are somewhat atypical. Because of the severity of his presentation, initiation of amphotericin B could be considered if he fails to quickly respond to the current regimen. There is no known effective treatment for rabies. Thus, if his presentation is due to rabies encephalitis, rabies vaccine and immunoglobulin will not be effective at treating active rabies infection. However, given his exposure history and the dogs' unvaccinated status, postexposure prophylaxis was appropriate to prevent future development of rabies. The inspiratory collapse and hyperdynamic ventricular response seen on his bedside echocardiogram is consistent with decreased effective circulating volume from sepsis or severe hypovolemia rather than acute heart failure.
Less than 36 hours after admission (60 hours after his symptoms began), the patient's oxygenation status had not improved. He developed diffuse cutaneous purpura with hemorrhagic bullae. Liver, renal, and cardiac function markers were all markedly abnormal. All cultures from the transferring hospital, collected before antibiotics were initiated, were negative to date. However, Gram stain of blood cultures performed at the academic medical center revealed possible gram‐negative rods. The patient remained unresponsive without sedation. ECG revealed evidence of inferior and anterolateral ischemia. The patient's family was informed of his persistently deteriorating condition and elected to pursue comfort measures. Two hours later the patient expired. The family agreed to an autopsy.
This patient succumbed to overwhelming sepsis and multiorgan failure. Although the etiologic pathogen is not immediately clear, several clues point to a likely unifying diagnosis. First, he has a history of a recent dog bite with minimal local evidence of infection. Second, he presented with fulminant sepsis with DIC, hemolytic anemia, and diffuse mottling that progressed to purpura fulminans. Third, a possible gram‐negative rod was isolated on blood Gram stain. Fourth, he has a history of heavy alcohol use. For these reasons, Capnocytophaga canimorsus is the most likely underlying etiology. C canimorsus is a fastidious gram‐negative coccobacillus that is an uncommon cause of fulminant sepsis in patients with dog bites. It is difficult to isolate due to culture growth requirements, which may explain the negative blood cultures in this case. Patients with alcoholism are predisposed to fulminant sepsis from C canimorsus, which often presents with hepatic and renal failure. The myocardial ischemia may be secondary to the metabolic and thrombotic complications of sepsis.
On autopsy, there was purpura fulminans involving over 90% of the total body surface area as well as skin slippage and loose bullae of greater than 75% of the total body surface area. There was infarction of the kidneys, liver, spleen, and adrenal glands as well as focal contraction bands of necrosis of the myocardium. The lungs showed diffuse alveolar damage. There was hemorrhage, edema, and necrosis seen in sections taken from the puncture wounds. Following the patient's death, it was reported by the transferring institution that C canimorsus was identified from 2 of 2 antemortem blood cultures, and pan‐sensitive Acinetobacter lwoffii in 1 of 2 blood cultures, though no sensitivities were performed on the C canimorsus isolate. In addition, antemortem cultures obtained at the academic medical center identified Capnocytophaga species in 1 of 2 peripheral blood culture specimens; sensitivities were not performed. Autopsy determined the cause of death in this patient to be septic complications of dog bite.
COMMENTARY
Dog bites are frequent, with over 12,000 occurring daily in the United States; of these, approximately 20% require medical attention.[1] Although most patients rapidly recover with conservative management, even initially benign‐appearing injuries can lead to long‐term morbidity or death. The hands are most often affected and are associated with more frequent need for both antibiotics and surgical intervention.[2, 3] The severity of injury does not correlate with subsequent infections.[3]
Management of dog bite injuries includes careful wound management. All patients with moderate to severe injury should be assessed within 48 hours by physical examination and radiography to assess the degree of injury and any associated nerve, tendon, joint, or bone damage. If there is concern for rabies based on history or vaccination status of the animal, prompt irrigation and debridement is crucial. Antimicrobial prophylaxis, typically with amoxicillinclavulanate, should be given to high‐risk patients, such as those with cirrhosis, asplenia, or other immunosuppressing conditions.[4] Most infections are caused by Pasteurella and Bacteroides, whereas Capnocytophaga may cause severe disease, particularly in patients with immunosuppression or excessive alcohol intake.[5] This patient was at increased risk of infection due to his late presentation following the initial bite and consequent delayed wound care, injury to the hand, and his history of alcoholism.[4]
Several members of the genus Capnocytophaga have been found in the oral cavities of both humans and canines. C canimorsus, found only in canine or feline oral cavities, is the only member of the genus known to cause human disease.[6] It is a fastidious gram‐negative rod requiring an environment enriched with carbon dioxide, making it notoriously difficult to isolate. Cultures typically do not show growth for 5 to 7 days; thus, it is not surprising all cultures were initially negative in this case.[4, 7] C canimorsus is a well‐described cause of sepsis related to dog bites, with some cases bearing similarity to fulminant meningococcal disease.[8] Severe illness typically occurs in immunosuppressed patients, particularly those with asplenia or cirrhosis.[9, 10] The pathophysiology of fulminant C canimorsus infections is not well described. It has been suggested that certain strains may produce a toxin that inhibits macrophages and inactivates tumor necrosis factor in humans, although this is not yet widely accepted.[11] Treatment of C canimorsus involves early administration of effective antimicrobials, supportive care, and standard management of the bite injury. C canimorsus is susceptible to several classes of antibiotics; ‐lactams, such as penicillin derivatives and cephalosporins, and potentiated sulphonamides, such as trimethoprim/sulfamethoxazole, typically have the best in vitro activity.[12] As illustrated in this case, even with prompt, effective antibiotic administration, C canimorsus infection can progress to DIC, multisystem organ failure, and death.[9]
A lwoffii was also identified, but was almost certainly a contaminant. It is a gram‐negative bacillus that is widely distributed throughout the environment. Commonly found on human skin and within the human oropharynx, it rarely causes human disease. Clinical manifestations of infection with A lwoffii are typically mild, and include superficial skin and soft tissue infection, urinary tract infection, and rarely bacteremia. Because of the severe presentation in this case and the compelling alternative explanation of C canimorsus, A lwoffii was almost certainly a contaminant.
Rabies was an intriguing possibility in this case given the unvaccinated status of the dogs and the patient's prominent neurologic findings. Clinicians must consider the possibility of rabies in any patient with a bite injury from an unvaccinated dog. However, rabies remains extremely rare in the developed world as a result of the overwhelming success of animal vaccination and postexposure prophylaxis. Furthermore, rabies typically has an incubation period of several months. If rabies had caused this patient's presentation, rabies immunoglobulin would have been ineffective. Nevertheless, rabies prophylaxis with rabies immunoglobulin and vaccination is appropriate to prevent subsequent disease unless rabies infection can be definitively excluded.[13]
This patient presented with septic shock, DIC, and multisystem organ failure after a dog bite. The discussant quickly recognized the propensity of Capnocytophaga to cause this constellation of findings in alcoholic patients after dog bites. This patient did not have cirrhosis or asplenia, both of which are known risk factors for C canimorsus infection; however, the fulminant presentation made C canimorsus a necessary consideration. Ultimately, the dramatic nature of the patient's presentation combined with his history of heavy alcohol intake led the discussant to the correct diagnosis of septic shock secondary to C canimorsus infection complicating a benign‐appearing dog bite. Clinicians caring for patients who present with sepsis after a recent dog bite should consider C canimorsus, remembering that on occasion, a dog's bark may not be bigger than his bite.
TEACHING POINTS
- The initial management of moderate or severe dog‐bite injuries includes careful wound assessment and radiography to exclude any associated bone, nerve, joint, or tendon injury.
- Immunosuppressed patients with dog bites, including those with cirrhosis or asplenia, should receive amoxicillin/clavulanate prophylaxis.
- C canimorsus is a fastidious gram‐negative bacillus that may cause fulminant sepsis after dog bites. It is associated with DIC, purpura fulminans, and multisystem organ failure.
- ‐lactam antibiotics, such as penicillin derivatives or cephalosporins, or sulphonamides, are the treatment of choice for C canimorsus.
Disclosure
Nothing to report.
A 58‐year‐old male presented to a local community hospital emergency department with fever and altered mental status. Earlier in the day he had complained of chills, swollen tongue, numbness and tingling in his extremities with associated burning pain, and generalized weakness. En route to the emergency department, he was extremely agitated and moving uncontrollably. On arrival, he was noted to be in respiratory distress and was intubated for hypoxic respiratory failure. He was subsequently transferred to an academic medical center, and in transit was noted to have sustained supraventricular tachycardia with a heart rate of 160 beats per minute.
Although the differential for altered mental status is broad, associated fever limits the main diagnostic considerations to infectious, toxic, and some inflammatory disorders. Confusion and fever are most concerning for a central nervous system infection, either meningitis or encephalitis. Sepsis from a broader range of infectious etiologies may also present with these symptoms. His respiratory failure could represent acute respiratory distress syndrome (ARDS) due to sepsis, aspiration, or a manifestation of a multisystem inflammatory disease.
He did not have any significant past medical or surgical history. Three days before his initial presentation, the patient was bitten on the left hand and forearm while breaking up a dogfight. The dogs that bit him belonged to his son, but were unvaccinated. He did not seek medical attention and it was unclear how he treated his wounds at home.
Dogs may serve as vectors for a number of zoonoses. Species of both Pasteurella and Capnocytophaga may cause sepsis and rarely meningitis as a consequence of dog bites. The incubation period of 3 days, though brief, does not exclude either infection. Rabies encephalitis is also possible, particularly given the dogs' unvaccinated status. However, the typical incubation period for rabies is on the order of months, and a 3‐day interval from inoculation to symptoms would be highly unusual. Although other explanations for his symptoms are more likely, he should still be considered for vaccination and rabies immune globulin. The dogs should be observed for clinical manifestations of rabies. Despite the patient's history of dog bite, a broad differential diagnosis must be maintained.
The patient lived in Michigan and worked in a chemical factory driving equipment without any hazardous exposures. He did not have any allergies. He drank 6 beers per day; he did not smoke cigarettes and had no history of illicit drug use. He was single and had 4 adult children.
His history of heavy alcohol consumption raises several additional possibilities. Delirium tremens, alcohol withdrawal seizures, or hepatic encephalopathy as a consequence of alcoholic cirrhosis are both potential contributors to his presentation. Furthermore, the physiologic signs of alcohol withdrawal are similar to many critical illnesses, which may present a diagnostic challenge. The patient's history of employment at a chemical factory is intriguing, though the details of any potential occupational exposures are unknown. Carbon monoxide poisoning can present with altered mental status and agitation, whereas anticholinergic toxicity can present with fever, tachycardia, and altered mental status; however, there is no obvious source of exposure to either.
On physical examination, the patient was intubated with a Glasgow Coma Scale of 11 without sedation; serial examinations revealed a fluctuating level of consciousness. His temperature was 38.1C, heart rate was 158 beats per minute, and blood pressure was 93/68 mm Hg. Mechanical ventilation was provided with assist control mode, a respiratory rate of 28 breaths per minute, tidal volume 466 mL, and positive end expiratory pressure of 20 cm of water. His oxygen saturation was 81% on 100% oxygen. Examination of his neck exhibited a large left neck hematoma from the unsuccessful placement of an external jugular intravenous catheter. Pupils were 4 mm in diameter and minimally reactive. There was no scleral icterus. Cardiac exam revealed tachycardia and regular rhythm without murmurs, rubs, or gallops. Lung exam was significant for bilateral rhonchi and minimal tracheal secretions. Extremity exam revealed 0.25 to 1.5 cm in diameter puncture bite marks with abrasions on his left third and fourth upper extremity digits as well as on his left forearm. Skin exam was diffusely cool with a mottled appearance. Neurologic exam revealed absent deep tendon reflexes throughout and apparent flaccid paralysis of all 4 extremities. Examination of the abdomen, lymph nodes, mouth, and throat were unremarkable.
The shock associated with sepsis is typically distributive, with intense vasodilation that classically leads to warm extremities. His mottled, cool extremities raise concern for disseminated intravascular coagulation (DIC), which can be seen in patients with septic shock, particularly cases caused by meningococcal disease and Capnocytophaga infections. His neurologic examination is typical of lower motor neuron disease, although acute upper motor neuron lesions can also be associated with hyporeflexia. Rabies can manifest as flaccid paralysis, but this would classically predate the mental status changes. Rabies remains a consideration, albeit a less likely one. Zoonoses, particularly Capnocytophaga and Pasteurella, are possible; however, a thorough search for other infections leading to sepsis is still indicated. His lung findings suggest severe ARDS.
The white blood cell count was 5,900/mm3, with 91% neutrophils, 6.6% lymphocytes, and 0.5% monocytes. The hemoglobin level was 13.0 g/dL, and the platelet count was 12,000/mm3. The fibrinogen level was 89 mg/dL (normal range 200400 mg/dL), international normalized ratio and partial‐thromboplastin time were 4.6 (normal range 0.8 to 1.1) and greater than 120.0 seconds (normal range 2535 seconds), respectively. Lactate dehydrogenase level was 698 IU/L (normal 120240 IU/L), and haptoglobin was 54 mg/dL (normal 41165 mg/dL). Serum sodium was 136 mmol/L, potassium 4.6 mmol/L, chloride 101 mmol/L, bicarbonate 16 mmol/L, blood urea nitrogen 29 mg/dL, creatinine 2.28 mg/dL, glucose 123 mg/dL, calcium 7.0 mg/dL, magnesium 1.7 mg/dL, and phosphorus 7.2 mg/dL. Total protein was 4.3 g/dL (normal 6.08.3 g/dL), albumin 2.5 g/dL (normal 3.54.9 g/dL), total bilirubin 2.3 mg/dL (normal 0.21.2 mg/dL), aspartate aminotransferase 71 IU/L (normal 830 IU/L), alanine aminotransferase 29 IU/L (normal 735 IU/L), and alkaline phosphatase 107 IU/L (normal 30130 IU/L). The serum troponin‐I level was 0.76 ng/mL, creatine phosphokinase 397 ng/mL, and creatine kinase‐myocardial band 3.5 ng/mL. Initial arterial blood gas analysis revealed a pH of 7.00, pCO2 57 mm Hg, pO2 98 mm Hg, and a lactic acid of 6.5 mmol/L (normal 0.52.2 mmol/L).
The patient has a normal absolute white blood cell count in the setting of septic shock. He has a relative neutrophilia and a marked leukopenia, both of which can be seen in overwhelming infections. The patient's arterial blood gas analysis indicates he has a mixed metabolic and respiratory acidosis. The normal physiologic response to metabolic acidosis is to increase minute ventilation and induce a compensatory respiratory alkalosis. His concomitant respiratory acidosis in the face of mechanical ventilation and presumed adequate minute ventilation suggests severely impaired alveolar gas exchange, most likely from ARDS. He has numerous other metabolic abnormalities, including acute kidney injury, DIC, and hemolytic anemia, all of which may be seen with severe bacterial infections or septic shock. Neisseria meningitidis and other gram‐negative infections would be of particular concern in this case. The combination of fever, altered mental status, thrombocytopenia, hemolytic anemia, and renal failure could be consistent with thrombotic thrombocytopenic purpura. However, the prolonged coagulation studies are much more consistent with DIC.
Intravenous antimicrobials were administered including ceftriaxone (initiated in the emergency department of the transferring hospital), ampicillin, vancomycin, piperacillin/tazobactam, clindamycin, metronidazole, doxycycline, and acyclovir. He received tetanus and rabies vaccines as well as tetanus and rabies immune globulin. The patient was given aggressive intravenous crystalloid fluids with minimal response in blood pressure. Intravenous norepinephrine was initiated to maintain a mean arterial pressure above 65 mm Hg. A plain chest radiograph (Figure 1) revealed perihilar airspace opacities. Head computed tomography without contrast revealed global cerebral volume loss greater than expected for the patient's age; no evidence of intracranial hemorrhage, mass effect, or edema; and proptosis of the eyes with adjacent preseptal soft tissue swelling without evidence of retrobulbar hemorrhage or vascular engorgement. Ultrasound of the left neck hematoma was negative for pulsatile mass. Electrocardiogram (ECG) revealed sinus tachycardia without evidence of ischemic changes. A bedside transthoracic echocardiogram showed hyperdynamic changes without evidence of hypokinesis but with inspiratory collapse of the inferior vena cava. Abdominal ultrasound was normal. Plain radiographs of the left hand (Figure 2) identified only mild soft tissue swelling over the dorsum of the hand. An ultrasound of the left hand and left forearm did not identify any abnormal fluid collection. A dialysis catheter was placed after the patient received platelets and fresh frozen plasma for initiation of continuous renal replacement therapy.
Given this patient's fulminant presentation, he was appropriately started on a very broad anti‐infective regimen. Although fungal infections are less likely, his current antimicrobial regimen lacks antifungal coverage. His finding of proptosis raises concern for mucormycosis, although the time course and clinical presentation are somewhat atypical. Because of the severity of his presentation, initiation of amphotericin B could be considered if he fails to quickly respond to the current regimen. There is no known effective treatment for rabies. Thus, if his presentation is due to rabies encephalitis, rabies vaccine and immunoglobulin will not be effective at treating active rabies infection. However, given his exposure history and the dogs' unvaccinated status, postexposure prophylaxis was appropriate to prevent future development of rabies. The inspiratory collapse and hyperdynamic ventricular response seen on his bedside echocardiogram is consistent with decreased effective circulating volume from sepsis or severe hypovolemia rather than acute heart failure.
Less than 36 hours after admission (60 hours after his symptoms began), the patient's oxygenation status had not improved. He developed diffuse cutaneous purpura with hemorrhagic bullae. Liver, renal, and cardiac function markers were all markedly abnormal. All cultures from the transferring hospital, collected before antibiotics were initiated, were negative to date. However, Gram stain of blood cultures performed at the academic medical center revealed possible gram‐negative rods. The patient remained unresponsive without sedation. ECG revealed evidence of inferior and anterolateral ischemia. The patient's family was informed of his persistently deteriorating condition and elected to pursue comfort measures. Two hours later the patient expired. The family agreed to an autopsy.
This patient succumbed to overwhelming sepsis and multiorgan failure. Although the etiologic pathogen is not immediately clear, several clues point to a likely unifying diagnosis. First, he has a history of a recent dog bite with minimal local evidence of infection. Second, he presented with fulminant sepsis with DIC, hemolytic anemia, and diffuse mottling that progressed to purpura fulminans. Third, a possible gram‐negative rod was isolated on blood Gram stain. Fourth, he has a history of heavy alcohol use. For these reasons, Capnocytophaga canimorsus is the most likely underlying etiology. C canimorsus is a fastidious gram‐negative coccobacillus that is an uncommon cause of fulminant sepsis in patients with dog bites. It is difficult to isolate due to culture growth requirements, which may explain the negative blood cultures in this case. Patients with alcoholism are predisposed to fulminant sepsis from C canimorsus, which often presents with hepatic and renal failure. The myocardial ischemia may be secondary to the metabolic and thrombotic complications of sepsis.
On autopsy, there was purpura fulminans involving over 90% of the total body surface area as well as skin slippage and loose bullae of greater than 75% of the total body surface area. There was infarction of the kidneys, liver, spleen, and adrenal glands as well as focal contraction bands of necrosis of the myocardium. The lungs showed diffuse alveolar damage. There was hemorrhage, edema, and necrosis seen in sections taken from the puncture wounds. Following the patient's death, it was reported by the transferring institution that C canimorsus was identified from 2 of 2 antemortem blood cultures, and pan‐sensitive Acinetobacter lwoffii in 1 of 2 blood cultures, though no sensitivities were performed on the C canimorsus isolate. In addition, antemortem cultures obtained at the academic medical center identified Capnocytophaga species in 1 of 2 peripheral blood culture specimens; sensitivities were not performed. Autopsy determined the cause of death in this patient to be septic complications of dog bite.
COMMENTARY
Dog bites are frequent, with over 12,000 occurring daily in the United States; of these, approximately 20% require medical attention.[1] Although most patients rapidly recover with conservative management, even initially benign‐appearing injuries can lead to long‐term morbidity or death. The hands are most often affected and are associated with more frequent need for both antibiotics and surgical intervention.[2, 3] The severity of injury does not correlate with subsequent infections.[3]
Management of dog bite injuries includes careful wound management. All patients with moderate to severe injury should be assessed within 48 hours by physical examination and radiography to assess the degree of injury and any associated nerve, tendon, joint, or bone damage. If there is concern for rabies based on history or vaccination status of the animal, prompt irrigation and debridement is crucial. Antimicrobial prophylaxis, typically with amoxicillinclavulanate, should be given to high‐risk patients, such as those with cirrhosis, asplenia, or other immunosuppressing conditions.[4] Most infections are caused by Pasteurella and Bacteroides, whereas Capnocytophaga may cause severe disease, particularly in patients with immunosuppression or excessive alcohol intake.[5] This patient was at increased risk of infection due to his late presentation following the initial bite and consequent delayed wound care, injury to the hand, and his history of alcoholism.[4]
Several members of the genus Capnocytophaga have been found in the oral cavities of both humans and canines. C canimorsus, found only in canine or feline oral cavities, is the only member of the genus known to cause human disease.[6] It is a fastidious gram‐negative rod requiring an environment enriched with carbon dioxide, making it notoriously difficult to isolate. Cultures typically do not show growth for 5 to 7 days; thus, it is not surprising all cultures were initially negative in this case.[4, 7] C canimorsus is a well‐described cause of sepsis related to dog bites, with some cases bearing similarity to fulminant meningococcal disease.[8] Severe illness typically occurs in immunosuppressed patients, particularly those with asplenia or cirrhosis.[9, 10] The pathophysiology of fulminant C canimorsus infections is not well described. It has been suggested that certain strains may produce a toxin that inhibits macrophages and inactivates tumor necrosis factor in humans, although this is not yet widely accepted.[11] Treatment of C canimorsus involves early administration of effective antimicrobials, supportive care, and standard management of the bite injury. C canimorsus is susceptible to several classes of antibiotics; ‐lactams, such as penicillin derivatives and cephalosporins, and potentiated sulphonamides, such as trimethoprim/sulfamethoxazole, typically have the best in vitro activity.[12] As illustrated in this case, even with prompt, effective antibiotic administration, C canimorsus infection can progress to DIC, multisystem organ failure, and death.[9]
A lwoffii was also identified, but was almost certainly a contaminant. It is a gram‐negative bacillus that is widely distributed throughout the environment. Commonly found on human skin and within the human oropharynx, it rarely causes human disease. Clinical manifestations of infection with A lwoffii are typically mild, and include superficial skin and soft tissue infection, urinary tract infection, and rarely bacteremia. Because of the severe presentation in this case and the compelling alternative explanation of C canimorsus, A lwoffii was almost certainly a contaminant.
Rabies was an intriguing possibility in this case given the unvaccinated status of the dogs and the patient's prominent neurologic findings. Clinicians must consider the possibility of rabies in any patient with a bite injury from an unvaccinated dog. However, rabies remains extremely rare in the developed world as a result of the overwhelming success of animal vaccination and postexposure prophylaxis. Furthermore, rabies typically has an incubation period of several months. If rabies had caused this patient's presentation, rabies immunoglobulin would have been ineffective. Nevertheless, rabies prophylaxis with rabies immunoglobulin and vaccination is appropriate to prevent subsequent disease unless rabies infection can be definitively excluded.[13]
This patient presented with septic shock, DIC, and multisystem organ failure after a dog bite. The discussant quickly recognized the propensity of Capnocytophaga to cause this constellation of findings in alcoholic patients after dog bites. This patient did not have cirrhosis or asplenia, both of which are known risk factors for C canimorsus infection; however, the fulminant presentation made C canimorsus a necessary consideration. Ultimately, the dramatic nature of the patient's presentation combined with his history of heavy alcohol intake led the discussant to the correct diagnosis of septic shock secondary to C canimorsus infection complicating a benign‐appearing dog bite. Clinicians caring for patients who present with sepsis after a recent dog bite should consider C canimorsus, remembering that on occasion, a dog's bark may not be bigger than his bite.
TEACHING POINTS
- The initial management of moderate or severe dog‐bite injuries includes careful wound assessment and radiography to exclude any associated bone, nerve, joint, or tendon injury.
- Immunosuppressed patients with dog bites, including those with cirrhosis or asplenia, should receive amoxicillin/clavulanate prophylaxis.
- C canimorsus is a fastidious gram‐negative bacillus that may cause fulminant sepsis after dog bites. It is associated with DIC, purpura fulminans, and multisystem organ failure.
- ‐lactam antibiotics, such as penicillin derivatives or cephalosporins, or sulphonamides, are the treatment of choice for C canimorsus.
Disclosure
Nothing to report.
- , , , . Dog bites: still a problem? Injury Prev. 2008;14(5):296–301.
- , , , . Dog bite injuries: primary and secondary emergency department presentations—a retrospective cohort study. ScientificWorldJournal. 2013;2013:393176.
- , , , et al. Management of vascular trauma from dog bites. J Vascular Surg. 2013;58(5):1346–1352.
- , . Dog bites. BMJ. 2007;334(7590):413–417.
- , , , . Bacterial infections as complications of dog bites [in Danish]. Ugeskrift Laeger. 1998;160(34):4860–4863.
- , , , , . Bite‐related and septic syndromes caused by cats and dogs. Lancet Infect Dis. 2009;9(7):439–447.
- , , , , . Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med. 1999;340(2):85–92.
- , , , . Diagnosing Capnocytophaga canimorsus infections. Emerg Infect Dis. 2006;12(2):340–342.
- , , . Capnocytophaga canimorsus septicemia in Denmark, 1982–1995: review of 39 cases. Clinical Infect Dis. 1996;23(1):71–75.
- . Consequences of alcohol consumption on host defence. Alcohol Alcohol. 1999;34(6):830–841.
- , , , , , . Molecular characterization of Capnocytophaga canimorsus and other canine Capnocytophaga spp. and assessment by PCR of their frequencies in dogs. J Clin Microbiol. 2009;47(10):3218–3225.
- , , , . The bacteriology and antimicrobial susceptibility of infected and non‐infected dog bite wounds: fifty cases. Vet Microbiol. 2008;127(3‐4):360–368.
- U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Human rabies—Alabama, Tennessee, and Texas, 1994. Morbidity and Mortality Weekly Report; 1995. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00036736.htm. Accessed March 1, 2014.
- , , , . Dog bites: still a problem? Injury Prev. 2008;14(5):296–301.
- , , , . Dog bite injuries: primary and secondary emergency department presentations—a retrospective cohort study. ScientificWorldJournal. 2013;2013:393176.
- , , , et al. Management of vascular trauma from dog bites. J Vascular Surg. 2013;58(5):1346–1352.
- , . Dog bites. BMJ. 2007;334(7590):413–417.
- , , , . Bacterial infections as complications of dog bites [in Danish]. Ugeskrift Laeger. 1998;160(34):4860–4863.
- , , , , . Bite‐related and septic syndromes caused by cats and dogs. Lancet Infect Dis. 2009;9(7):439–447.
- , , , , . Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med. 1999;340(2):85–92.
- , , , . Diagnosing Capnocytophaga canimorsus infections. Emerg Infect Dis. 2006;12(2):340–342.
- , , . Capnocytophaga canimorsus septicemia in Denmark, 1982–1995: review of 39 cases. Clinical Infect Dis. 1996;23(1):71–75.
- . Consequences of alcohol consumption on host defence. Alcohol Alcohol. 1999;34(6):830–841.
- , , , , , . Molecular characterization of Capnocytophaga canimorsus and other canine Capnocytophaga spp. and assessment by PCR of their frequencies in dogs. J Clin Microbiol. 2009;47(10):3218–3225.
- , , , . The bacteriology and antimicrobial susceptibility of infected and non‐infected dog bite wounds: fifty cases. Vet Microbiol. 2008;127(3‐4):360–368.
- U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Human rabies—Alabama, Tennessee, and Texas, 1994. Morbidity and Mortality Weekly Report; 1995. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00036736.htm. Accessed March 1, 2014.